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1 Abbreviations 
General 
APC    Antigen-presenting cell 
APO    Apolipoprotein 
BCA    Bicinchoninic acid 
BLS    Bare lymphocyte syndrome 
CCL    C-C motif ligand 
CD    Cluster of differentiation 
CFSE    Carboxyfluorescein succinimidyl ester 
CGD    Chronic granulomatous disease 
CIITA    Class II major histocompatibility complex transactivator 
Cl-    Chloride ion 
CLR    C-type lectin receptor 
CR    Complement receptor 
CREB    cAMP response element-binding protein 
CTLA    Cytotoxic T-lymphocyte-associated protein 
CXC    C-X-C motif 
DCs    Dendritic cells 
DNA    Desoxyribonucleic acid 
DPI    Diphenyleneiodonium 
DPPI    Pipeptidyl peptidase I 
ERK    Extracellular-signal regulated kinase 
FBS    Fetal bovine serum 
FcR    Fc receptor 
fMLP    N-Formylmethionine-leucyl-phenylalanine 
GCP    Good clinical practice 
GM-CSF   Granulocyte-macrophage colony-stimulating factor 
GMP    Granulocyte-monocyte myeloid progenitor 
H+    Hydrogen ion 
H2O2    Hydrogen peroxide 
HLA    Human leukocyte antigen 
HOCl    Hypochlorite 
IFN-γ    Interferon gamma 
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IgG    Immunoglobulin G 
IL    Interleukin 
JAK    Janus kinase 
JNK    c-Jun-N-terminal kinase 
K+    Potassium Ion 
LB    Luria-Bertani 
LC-MS    Liquid chromatography-mass spectrometry 
LMPP    Lymphoid-primed multipotent progenitor 
LN    Lymph node 
LPS    Lipopolysaccharide 
LTB4    Leukotriene B4 
LysM    Lysozyme M gene 
MAIT    Mucosa-associated invariant T cells 
MAPK    Mitogen-activated protein kinase 
MCP    Monocyte chemotactic protein 
MDSC    Myeloid-derived suppressor cells 
MEK    Kinase of mitogen-activated protein kinase 
MHC    Major histocompatibility complex 
MOI    Multiplicity of infection 
MPO    Myeloperoxidase 
MSK    Mitogen- and stress-activated protein kinase 
mTOR    Mechanistic target of rapamycin 
NADPH   Nicotinamide adenine dinucleotide phosphate 
NETs    Neutrophil extracellular traps 
NFY    Nuclear transcription factor Y 
NK cells   Natural killer cells 
NO    Nitric oxide 
O2    Oxygen 
O2*    Singlet oxygen 
O2-    Superoxide 
OH-    Hydroxyl radical 
OT    Ovalbumin-specific T cells 
OVA    Ovalbumin 
PAMP    Pathogen-associated molecular pattern 
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PBMC    Peripheral blood mononuclear cell 
PBS    Phosphate buffered saline 
(RT)- PCR   (Reverse transcription)- Polymerase chain reaction 
PD1    Programmed cell death 1 
PDK    Phosphoinositide-dependent kinase 
PEC    Peritoneal exudate cell 
PI    Propidium iodide 
PI3K    Phosphoinositide 3-kinase 
PKA    Protein kinase A 
PMA    Phorbol-12-myristate-13-acetate 
PMN    Polymorphonuclear neutrophils 
PRR    Pattern recognition receptor 
qSOFA   quick Sequential organ failure assessment 
RFP    Red fluorescent protein 
RFX    Regulatory factor X 
RFXANK   Regulatory factor X-associated ankyrin-containing protein  
RFXAP   Regulatory factor X-associated protein 
ROS    Reactive oxygen species 
RSK    Ribosomal S6 kinase 
SNAP    Synaptosomal-associated proteins 
STAT    Signal transducer and activator of transcription 
TAN    Tumour-associated neutrophils 
TCR    T-cell receptor 
TGF    Transforming growth factor 
TH1    T helper subset 1 
TH2    T helper subset 2 
TIM-3    T cell molecule with immunoglobulin and mucin domain 3 
TLR    Toll-like receptor 
TNF-α    Tumour necrosis factor alpha 
TRAIL    Tumour necrosis factor-related apoptosis-inducing ligand 
TReg cells   Regulatory T cells 
US    United States 
VEGF    Vascular endothelial growth factor 
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Microbes 
C. albicans   Candida albicans 
A. fumigatus   Aspergillus fumigatus 
E. coli    Escherichia coli 
S. aureus   Staphylococcus aureus 
L. monocytogenes  Listeria monocytogenes 
M. tuberculosis  Mycobacterium tuberculosis 
A. phagocytophilum  Anaplasma phagocytophilum 
C. pneumoniae  Chlamydophila pneumoniae 
S. typhimurium  Salmonella typhimurium 
 
Units 
CFU    Colony-forming units 
h    hour 
min    minute 
s    second 
µ    micro 
n    nano  
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2 Summary  
Pathogen clearance in infectious diseases strongly depends on a fine-tuned interplay 
between innate and adaptive immunity. Undoubtedly, neutrophils as first line defense 
against invading pathogens play a major role to recognize, phagocytose and kill the 
invaders. However, the diverse role of neutrophils under inflammatory conditions in 
infectious diseases has been largely ignored so far.  
In my PhD thesis, I addressed the implications of the versatile neutrophil functions in 
immunity encountering pathogenic microorganisms that cause infectious diseases. In 
particular, experimental approaches with human neutrophils from healthy individuals and 
from patients suffering from various infectious diseases and immunological disorders, 
respectively, were combined with a mouse model of Salmonella infection with the help of 
techniques such as flow cytometry, reverse transcription- polymerase chain reaction (RT-
PCR) and proteomics to reveal the so far underestimated diversity in neutrophil function. 
We showed that “simple foot soldier” neutrophils are important for host defense against 
bacterial and fungal pathogens. With the help of the nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase and myeloperoxidase (MPO), neutrophils are able to produce 
large amounts of reactive oxygen species (ROS) that are important for pathogen 
destruction. We could show that neutrophils from patients receiving allogeneic 
hematopoietic stem cell transplantations (HSCT) have significantly impaired ROS 
production against Candida (C.) albicans and Aspergillus (A.) fumigatus. However, ROS 
can also cause detrimental damage in host tissues. We showed that MPO, one of the key 
enzymes in ROS production, has a protective role in the host by scavenging diffusible 
hydrogen peroxide (H2O2) at the Salmonella surface and converting it into highly reactive 
hypochlorite (HOCl) within a short reach. This sophisticated mechanism of MPO- to confine 
potential harmful molecules to the pathogen microenvironment- leads to both effective 
pathogen destruction and minimal collateral host tissue damage.  
Neutrophils as “versatile commanders” are unambiguously involved in the pathogenesis of 
sepsis, the dysregulated host response to infection. We could observe that neutrophils and 
monocytes accumulate neutral lipids during Salmonella infection and change their lipid 
metabolic program in sepsis comparable to atherosclerosis. Moreover, we identified a 
subset of antigen-presenting cell (APC)-like neutrophils with major histocompatibility 
complex (MHC) class II molecule expression, which could be induced under inflammatory 
conditions. The inflammatory environment triggers highly specific signaling pathways in 
neutrophils that orchestrate intracellular protein phosphorylation cascades, finally leading 
to the formation of the MHC class II enhanceosome.   
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We could show that the MHC class II enhanceosome is responsible for the subsequent 
MHC class II expression on neutrophils and that targeting Janus kinase (JAK) 1/2 could be 
a promising therapeutic approach in sepsis to reach homeostasis. Overall, these data show 
that the immunological function of neutrophils in sepsis is highly versatile and goes far 
beyond simple pathogen destruction. Together, these data show that infectious disease 
control implies a specialized, but versatile immune system with diverse neutrophil 
functionality. 
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3 Introduction 
3.1 Neutrophil biology 
Neutrophils, also known as polymorphonuclear neutrophils (PMN) or granulocytes, are the 
most abundant immune cell type in the periphery making up to 70% of total leukocytes. 
They play a crucial role in the efficient innate immune defense against invading pathogens, 
but also contribute in the pathogenesis of autoimmunity, chronic inflammation and cancer 1.  
To compensate the high turnover rate, neutrophils are produced in large amounts in the bone 
marrow. Estimated two-thirds of bone marrow space are dedicated to the formation of 
neutrophils and monocytes in steady-state conditions 2. During granulopoiesis, neutrophil 
development starts from a common lymphoid-primed multipotent progenitor (LMPPs) and further 
differentiates into a granulocyte-monocyte myeloid progenitor cell (GMPs) under the influence of 
several transcription factors. The transition from GMP state to hyper-segmented, mature 
neutrophils is characterized by the full equipment of all granule subsets, which is typical for these 
immune cells 3. Fully differentiated neutrophils are released from bone marrow into periphery with 
a relatively short lifespan compared to other immune cells 4,5. A neutrophil has a diameter of 10-
15 µm and a volume of 346 µm3 with 3-to 5-lobe- segmented nucleus with randomly distributed 
chromosomes. Mitochondria are rare (1% of cell volume), thus glycolytic metabolism is preferred 
[Hallet MB, The Neutrophil: Cellular Biochemistry and physiology 1990; Chapter 1: The 
significance of stimulus- response coupling in the neutrophil for physiology and pathology]. 
Blood-circulating neutrophils are recruited to the site of infection or inflammation upon activation 
by a process called extravasation. Normally about 3% of total neutrophils in vivo are migrating 
into tissue upon demand and help to resolve the infection by several killing mechanisms 4. As 
professional phagocytes, neutrophils ingest and degrade pathogens in the phagolysosome by 
using oxygen-dependent and oxygen-independent mechanisms. The oxygen-dependent 
mechanism generates large amounts of reactive oxygen species (ROS), ultimately leading to 
DNA, protein and lipid damage, whereas the oxygen-independent mechanism is using potent 
antimicrobial substances, which are stored in the heterogeneous cytoplasmic granules 6. The 
oxygen-independent mechanism is referred to as degranulation and can lead to membrane 
permeabilization and hydrolysis of several biomolecules. However, the precise interplay between 
oxygen-dependent and oxygen-independent mechanisms in successful pathogen clearance is 
still unknown 7. Recently, the dogma that neutrophils are solely simple phagocytes with restricted 
pro-inflammatory resources is heavily challenged. Neutrophils can contribute to chronic 
inflammatory conditions and regulate a vast repertoire of adaptive immune responses 5, 
extending the so far underestimated diversity in neutrophil biology. 
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3.2 The life and death of a neutrophil 
Apoptosis as a special variant of cell death is an important mechanism for maintaining 
homeostasis of the immune system, especially for high abundant immune cells with a rapid 
turnover rate and potentially harmful cellular components such as neutrophils 8. During 
early stages of inflammation, a prolonged neutrophil survival is desirable to control the 
infection, but after resolution of infection a dampened response should be triggered to 
prevent inflammatory disorders and tissue damage. Apoptosis in neutrophils occurs in the 
absence of activation 9 and is accelerated upon phagocytosis by several pathogens 10, e.g. 
Escherichia coli (E. coli), Staphylococcus aureus (S. aureus), Listeria monocytogenes (L. 
monocytogenes), Mycobacterium tuberculosis (M. tuberculosis) 11, with exception of 
Anaplasma phagocytophilum (A. phagocytophilum) 12 and Chlamydophila pneumoniae (C. 
pneumoniae) 13 that delay neutrophil apoptosis. Furthermore, pro-inflammatory cytokines 
such as tumour necrosis factor (TNF)- α, interleukin (IL)-1β, IL-6, granulocyte colony-
stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) 
and Interferon gamma (IFN-γ) as well as some particular pathogen-associated molecular 
patterns (PAMPs), e.g. lipopolysaccharide, delay neutrophil apoptosis 14. During the 
apoptotic process, neutrophils are impaired in many classical effector functions such as 
chemotaxis, adhesion, phagocytosis, ROS production, and cytokine secretion 15. 
Historically, neutrophils were considered as short-lived cells with a half-life in the circulation 
of approximately 1.5 and 8 hours in mice and humans, respectively 5,16. However, recent 
findings show that the average circulatory lifespan of neutrophils in vivo is much longer 
than previously thought with up to 12.5 hours in mice and unprecedented 5.4 days in 
humans 17, but these data are still heavily debated 18,19. Nevertheless, neutrophils become 
activated under inflammatory conditions and their longevity increases by several fold 20,21. It 
is assumed that these long-living, primed neutrophils at the site of inflammation may 
change their phenotype under the influence of a particular cytokine-rich milieu 14,22 and may 
adapt novel immune cell functions 5. 
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3.3 Recruitment to the site of infection 
Active recruitment of neutrophils to the site of infection involves active mobilization out of 
peripheral blood and bone marrow, a process called extravasation. Potent host factors 
triggering recruitment are C-X-C motif ligand (CXCL) 8, leukotriene B4 (LTB4), CXCL1 and 
CXCL2 5. These chemokines are produced upon inflammation by monocytes, 
macrophages, mast cells, epithelial cells, fibroblasts and endothelial cells and specifically 
bind chemokine receptors C-X-C motif receptor (CXCR) 1, LTB4 receptor and CXCR2, 
respectively, on neutrophil surface. Further, bacteria can also produce molecules that 
directly attract neutrophils e.g. N-formylated peptides 23. The neutrophil “rolling process” in 
blood vessels, one of the first steps in extravasation, is mediated by C-type lectin 
glycoproteins known as selectins 24. E- and P-selectins are upregulated on the surface of 
activated endothelial cells and activated platelets 25. Not only cytokines, but also other 
factors such as LTB4, histamine or complement peptide C5a are able to induce selectin 
expression 26. E- and P- selectins interact with neutrophil CD162 (P-selectin glycoprotein 
ligand 1), thus facilitating neutrophil aggregation to endothelial tissue, a process called 
tethering 27. Tethering precedes adhesion by leukocyte adhesion molecules such as β1- 
(very late antigen-4) and β2- integrins (macrophage-1 antigen or lymphocyte function-
associated antigen 1) 28. Transmigration into tissue after tight adhesion is mediated by 
neutrophil surface molecules CD31 29, CD54 30, CD44 31 and CD47 32. 
3.4 Phagocytosis of microorganisms during infection 
At site of infection, neutrophils bind and ingest invading microorganisms, a process called 
phagocytosis. Neutrophils recognize conserved pathogen-associated molecular patterns 
(PAMPs) unique to microbial structures via pattern recognition receptors (PRRs). PRRs in 
neutrophils consist out of the family of toll-like receptors (TLRs), complement receptors 
(CR), Fc receptors (FcR) and C-type lectin receptors (CLR). The discovery of the germ-line 
encoded TLR family as key players in innate immunity brought high scientific attention and 
Nobel Prize in Medicine to Jules Hoffmann and Bruce Beutler in 2011 33. Human neutrophils 
express a repertoire of 9 different surface bound or soluble TLRs (TLR1, 2, 4-9 34), all involved 
in efficient uptake and engulfment of bacterial and fungal pathogens. Moreover, the 
efficiency of phagocytosis by neutrophils is drastically improved if microbes are opsonized 
with human serum proteins, such as complement components C3b, iC3b and Clq as well 
as antibodies.  
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Complement components are recognized by CR1 (CD35) 35, CR3 (CD11b/CD18) 36 and 
CR4 (CD11c/CD18) 37 on neutrophil surface and antibodies can be bound by FcγR1 (CD64, 
high affinity IgG receptor), FcγR2 (CD32, low affinity IgG receptor), FcγR3 (CD16, high 
affinity IgG receptor) 38 as well as IgE receptor FcεR1 (CD23) 39 and FcαR (CD89) 40. 
Altogether, TLRs, CRs, FcRs and CLRs contribute to the phagocytic process and 
subsequent pathogen elimination.  
3.5 Production of reactive oxygen species (ROS) as oxidative killing pathway 
Followed by phagocytic uptake of microorganisms, neutrophils start to produce ROS, a process 
known as oxidative burst or respiratory burst. ROS production is induced by an activated 
membrane-bound nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidase, 
which transfers electrons from cytosolic NADPH to extracellular or intraphagosomal molecular 
oxygen (O2), therefore producing short-lived superoxide (O2-) 41. The inactivated NADPH 
oxidase consists out of cytosolic p40phox, p47phox, p67phox, Rac2 42-44 and membrane-
bound flavocytochrome b558 (heterodimer out of gp91phox and p22phox 42,45). During 
phagocytic process, the cytosolic components translocate to the phagosomal membrane 
and associate with flavocytochrome b558, thus forming a functional NADPH oxidase 
capable in O2- generation 42. O2- can dismutate into hydrogen peroxide (H2O2) 
spontaneously 46 or enzymatically by superoxide dismutase 47. However, the process of 
H2O2 production is indispensable for neutral intraphagosomal pH maintenance 48. 
Another key enzyme in neutrophils, the myeloperoxidase (MPO), is released from 
azurophilic granules and converts almost all O2- or H2O2 into highly toxic hypohalous acids 
(OCl-, OBr-, OF- or OI-). Hypochlorite (HOCl) is the predominant ROS in the neutrophil 
phagosome if chloride supply is not limited. HOCl is a highly reactive oxidant with potent 
antimicrobial efficacy 49 and supposed to be the major oxidative weapon in neutrophils. 
Furthermore, hydroxyl radical (OH-) and singlet oxygen (O2*) contribute to microbicidal 
activity, too 50 (Fig. 1). 
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The relevance of NADPH oxidase and MPO in host immunity is reflected by the clinical 
impact of their deficiencies. Patients suffering from NADPH oxidase deficiency develop a 
severe disease called chronic granulomatous disease (CGD), characterized by mostly X-
linked recessive defect in the cytochrome b (588) subunit beta gene encoding the gp91-
phox subunit of the NADPH oxidase. CGD patients suffer from severe, recurrent bacterial 
and fungal infections due to defective O2- anion generation, resulting in attenuated 
antimicrobial activity 51,52. Interestingly, antimicrobial activity in CGD patients can be 
restored by introducing exogenous H2O2 in vitro 53. The incidence of CGD is estimated 
around 1 in 200’000. On the other hand, MPO deficiency is one of the most frequent 
inherited phagocytic disorders with a prevalence of 1 in 2000-4000 individuals in US/ 
Europe 54,55 respectively 1 in 20’000-60’000 individuals in Japan 56. Early epidemiological 
studies propose a correlation between MPO deficiency and cancer 57,58 and bacterial/ 
fungal infections, respectively 59,60. In strong contrast, other studies could not show any 
particular susceptibility to cancer or severe infections in MPO deficient patients 61,62. The 
reasons for these discrepancies among literature may be due to the clinical manifestation 
of partial and full MPO deficiency in human individuals, the follow-up and the investigated 
number of cases. Partial MPO deficient individuals still have residual MPO activity that 
might be sufficient for a protective antimicrobial immune response 54, whereas only the less 
prevalent, full MPO deficiency shows a clinical manifestation. This concept is in agreement 
with the finding that only individuals with full MPO deficiency fail to form neutrophil 
extracellular traps (NETs) 63 , an important antimicrobial protective response mechanism to 
large pathogens 64.  
Fig. 1: MPO-dependent events in 
human neutrophil phagosome. 
Concomitant with phagocytosis, the 
NADPH oxidase generates high 
fluxes of ROS (O2-) and MPO coverts 
the intracellular hydrogen peroxide 
(H2O2) into hypochlorite (HOCl), 
which can directly attack microbial 
targets. O2, oxygen; O2-, superoxide; 
Cpd1, compound 1; Cl, chloride; 
CFTR, cystric fibrosis conductance 
regulator. After Nauseef, Cell 
Microbiol. 2014. 
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Rare in vitro studies with human MPO deficient neutrophils are inconsistent. The first case report 
of a full MPO deficient individual dates back to 1969. His neutrophils in vitro have shown 
impaired killing capacity to Candida and Staphylococci 65, supported later by others 49,57. Another 
report could demonstrate that there have been only minor defects in S. aureus killing by 
MPO deficient neutrophils, whereas C. albicans killing was heavily impaired 59. In 
summary, MPO deficient neutrophils are still able to kill microbes with reactive oxygen 
species, although less efficiently 49. Nevertheless, the clinical consequence of MPO 
deficiency is not comparable with the phenotype observed in patients with NADPH oxidase 
deficiency. It can be speculated that MPO-independent microbicidal mechanisms increase 
their activity to compensate for the lack of MPO 62 or other ROS than HOCl can be 
produced, namely O2- and H2O2, and those can lead to antimicrobial killing 66. It is reported 
that those two ROS can generate the highly reactive hydroxyl radical (OH-) via the Fenton 
reaction, leading to severe DNA damage 67.  
Mice deficient in MPO infected with various pathogens show conflicting results. On one 
hand, MPO deficient mice have been more susceptible to infections with C. albicans 49,68,69, 
Aspergillus fumigatus (A. fumigatus) 68, Pseudomonas aeruginosa 68 and Klebsiella 
pneumoniae 70 than wildtype. On the other hand, there was no difference observed 
between MPO deficient and wildtype mice infected with Candida glabrata, S. aureus and 
Streptococcus pneumonia 49,68.  
Taken together, data from individuals lacking MPO and mice with MPO deficiency in 
infection are inconclusive and the role of ROS and MPO in infection control remains to be 
elucidated.  
3.6 Degranulation as a non-oxidative killing pathway 
Upon neutrophil phagocytosis of intracellular microorganisms, cytoplasmic granules are 
triggered to mobilize and fuse with the phagosomes 71, leading to the formation of the 
phagolysosome. The cytoplasmic granules are fully packed with a huge repertoire of 
antimicrobial peptides and proteases. The action of these antimicrobial agents constitutes 
to the non-oxidative killing pathway of neutrophils 72. The signalling pathway underlying 
granule mobilization has not been fully elucidated, but involves calcium-mediated signal 
transduction, Src family tyrosine kinases Gardner-Rasheed feline sarcoma and HCK, p38 
mitogen-activated protein kinases, synaptosomal-associated proteins (SNAPs) as well as SNAP 
receptors 73-77. Basically, there are four different granule types in neutrophils: The azurophilic 
(primary), the specific (secondary), gelatinase (tertiary) and secretory granules 78.  
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The granule classification is based on their protein content, their temporal biosynthesis during 
neutrophil differentiation in the bone marrow and their ability of exocytosis after pathogen 
engulfment 72. Azurophilic granules are very limited in exocytosis and contribute mainly to 
intracellular pathogen destruction in the phagolysosome 72. The fusion of azurophilic granules 
with the phagosome leads to enrichment of the phagosome lumen with antimicrobial agents 
(MPO, α-defensins, cathepsins, proteinase-3, elastase and azurocidin 78). MPO is considered to 
play a major role in the oxidative killing pathway, as mentioned above in details. α-defensins, a 
group of cationic polypeptides which interact with negatively charged surfaces 79, comprise up to 
50% in azurophilic granules and are able to rupture bacterial membranes 80. Moreover, α-
defensins can modulate innate immune responses inclusive chemotaxis and histamine release 
81. Cathepsins are powerful proteases that exert protein hydrolysis. The cathepsin family 
consists out of serine proteases (cathepsin A and G), aspartate proteases (cathepsin D and E) 
and cysteine proteases 82. Mice deficient in cathepsin G are more susceptible to infection with 
S. aureus 83. The precise killing mechanism of cathepsin G is unclear, but E. coli membrane 
disruption could be observed in vivo 84. Neutrophil proteinase 3 and elastase share many 
structural and functional homologies to cathepsin G. Mice deficient in elastase are more 
susceptible to infection with gram-negative pathogens such as E. coli, Klebsiella pneumoniae 
and several enterobacteria species 85,86. It has been shown that neutrophil elastase directly 
cleaves microbial virulence factors in Salmonella enterica serovar Typhimurium, Shigella 
flexneri and Yersinia enterocolitica 86. The lack of neutrophil elastase leads to phagosomal 
escape of bacteria, ultimately leading to prolonged survival in infected neutrophils 86. 
Interestingly, patients suffering from Papillon-Lefèvre syndrome (Loss- of- function mutation in 
the gene encoding dipeptidyl peptidase I, DPPI) 87 have an almost total loss of functional 
cathepsin G and neutrophil elastase, but still show normal neutrophil microbicidal activity 
against S. aureus and E. coli 88. These results highlight that efficient microbial killing does not 
fully rely on cathepsin G and neutrophil elastase.  
Specific granules, containing flavocytochrome b558 89, lactoferrin 90, cathelicidin and lysozyme 72 
contribute substantially to the potent microbicidal effect observed in neutrophils. Beside direct 
bacterial membrane permeabilization, lactoferrin sequesters iron originated from 
microorganisms, thus limiting bacterial growth 91. Lysozyme hydrolyses peptidoglycan, a major 
component of bacterial cell wall, especially in gram-positive bacteria 92. In conclusion, the 
importance of non-oxidative killing mechanisms for infection control is not fully understood. So 
far, the only clinically relevant disease associated with mutations in the non-oxidative killing 
pathway, the Papillon-Lefèvre syndrome, is not associated with higher burden of infectious 
complications. Thus, the interplay between oxidative and non-oxidative killing mechanisms 
should be highlighted in more details.  
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3.7 The interlink between oxidative and non-oxidative killing pathways 
Traditionally, the oxidative killing pathway by generating large quantities of ROS is thought 
to be responsible for the direct killing of microorganisms 72. This view is highly supported by 
the fact that CGD patients (lack of NADPH oxidase) succumb to severe systemic bacterial 
and fungal infections. However, this view is heavily challenged by Reeves et al. They have 
demonstrated that ROS may have limited capacity for direct microbicidal activity, opposite 
to the hitherto accepted view. More likely, non-oxidative killing by proteases shall be 
primarily responsible for pathogen destruction 83,93. According to their proposed model, the 
NADPH oxidase consumes O2 and generates O2- anions. To compensate the negative 
charge accumulation in the phagolysosome, cations are pumped into the phagosome 
across membrane (K+, H+). As a consequence of the K+ influx into the phagolysosome, 
serine proteases are activated, released from the sulphated proteoglycan matrix in the 
azurophilic granule and distributed among the lumen of the phagolysosome, thus leading to 
effective microbial destruction. Moreover, protonation of O2- anions in the phagosome 
generates H2O2. Accumulated H2O2 is used by MPO to produce the highly toxic HOCl. At 
the same time, solely by the catalytic oxidative activity of MPO, serine proteases are 
protected from collateral MPO-mediated inactivation and execute their deadly killing 
activity. In agreement with this concept, an early study by Vissers et al. has shown that 
neutrophil elastase activity is dependent on MPO-mediated H2O2/ Cl- chlorinating system 94. In 
contrast, another study could show that MPO is a direct oxidative inactivator of neutrophil 
elastase 70. Despite this effort to synergize oxidative and non-oxidative killing mechanisms, 
there are still many open questions in terms of the precise interplay between oxidative and 
non-oxidative killing mechanisms in neutrophils. However, a recent mechanism called 
neutrophil extracellular trap formation (NETosis) tries to answer some of those questions.  
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3.8 NETosis 
NETosis as a novel neutrophil killing mechanism has been described for the first time in 
2004 by Brinkmann et al 95. NETs are extracellular, web-like structures composed of 
nuclear and granular protein material with decondensed DNA or mitochondria-derived 
chromatin 95,96. NETs have the capacity to entrap and kill bacteria 95, fungi 97, viruses 98, 
parasites 99 and prevent pathogen dissemination 64. Moreover, NETosis occurs after pro-
inflammatory cytokine (IL-8, TNF-α) priming 100. 
The precise NET protein composition strongly depends on the stimulus 101. Initial studies 
have revealed 24 proteins in NETs upon activation with phorbol-12-myristate-13-acetate 
(PMA), including histones, neutrophil elastase, MPO, calprotectin, cathelicidins, defensins 
and actin 102. Studies with Pseudomonas aeruginosa mucoid and non-mucoid strains could 
induce NETosis with a composition of 33-50 different proteins, dependent on bacterial 
strain 103. The difference between NETosis and other forms of cell death is the 
characteristic loss of intracellular membranes. Later, the integrity of the plasma membrane 
is compromised, too 104.  
Interestingly, NETosis links intracellular oxidative and non-oxidative killing mechanisms to 
a novel, extracellular killing mechanism. In brief, ROS are generated by the NADPH 
oxidase and MPO. MPO activity leads to activation and nuclear translocation of neutrophil 
elastase, where it starts to proteolytically process histones and induces chromatin 
decondensation 105. Neutrophils from patients with CGD and diphenyleneiodonium (DPI)-
treated neutrophils from healthy individuals have shown a complete loss of NETosis in 
response to PMA and S. aureus, and exogenously added H2O2 could restore NETosis 104. 
In addition, NADPH oxidase-deficient mice have shown abrogated NETosis during 
pulmonary Aspergillosis infection 106. Both studies highlight the important role of NADPH 
oxidase-generated ROS fluxes in triggering NETosis. 
Patients suffering from full MPO deficiency fail to form NETs, in contrast to patients with 
partial MPO deficiency, who are still able to form NETs 63. In agreement with this finding, 
the pharmacological inhibition of the enzymatic activity of MPO cannot block but only delay 
NETosis 63. In summary, partially MPO deficient neutrophils or incompletely abrogated 
MPO activity in neutrophils are still able to induce NETosis.  
Mice defective in neutrophil elastase fail to form NETs in a Sendai virus infection 107 and a 
pulmonary Klebsiella pneumonia infection model 105. Similarly, neutrophils from patients with 
Papillon-Lefèvre syndrome with inactive neutrophil elastase are defective in NETosis 108,109.  
Mechanistically, a fraction of MPO and neutrophil elastase are bound in a complex called 
the azurosome, which spans granule membrane in resting neutrophil state 110. Upon 
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neutrophil activation, MPO orchestrates neutrophil elastase release from azurophilic 
granules independent from its enzymatic activity, thereby promoting neutrophil elastase- 
mediated actin cytoskeleton degradation in the cytosol and chromatin decondensation in 
the nucleus, ultimately committing neutrophils to NETosis 101,105. NETosis must be tightly 
regulated and pathogen size is one of the key factors that influence NETosis. Pathogen 
sensing depends on the limited access to neutrophil elastase via NETosis or 
phagocytosis. Small pathogens are taken up into the phagosome, fuse with azurophilic 
granules and use neutrophil elastase directly for antimicrobial destruction, thereby 
hindering neutrophil elastase from nuclear translocation and chromatin decondensation. 
Large pathogens (such as fungal hyphae or bacterial biofilm aggregates) cannot enter 
the phagosome, thus neutrophil elastase is freely available from azurophilic granules to 
induce NETosis 64. Opposite to this “neutrophil elastase availability model”, several other 
studies have revealed that the phagocytic process after NET formation in response to 
pathogens is not affected. Even after loss of DNA, anuclear neutrophils are still able to 
chase and phagocytose bacteria 111,112.  
In summary, NETosis is a potent antimicrobial mechanism, especially during infections 
with large pathogens, and combines both oxidative and non-oxidative killing mechanisms. 
3.9 The expanding repertoire of neutrophil-derived cytokines as 
immunomodulatory agents   
Phagocytosis in neutrophils does not only trigger killing mechanisms, but also induces 
transcriptional activity of a huge repertoire of immunomodulatory agents including 
Interleukin (IL)-1α, IL-1β, IL-1ε, IL-6, IL-8, IL-10, IL-12β, IL-15, IL-18, C-C motif ligand (CCL)-2 
(also macrophage inflammatory protein-1alpha), CCL3 (also macrophage inflammatory 
protein-1beta), CXCL1 (growth regulated oncogene-alpha), CXCL2 (macrophage inflammatory 
protein-2alpha), CXCL3 (macrophage inflammatory protein-2beta), CXCL12 (stromal cell-
derived factor 1), CCL20 (macrophage inflammatory protein-3alpha), tumour necrosis factor 
(TNF)-α and vascular endothelial growth factor (VEGF) 1,113,114. In a positive feedback 
manner, this cytokine response modulates additional PMNs and attracts macrophages, 
dendritic cells (DCs) and lymphocytes to site of infection. The secretion of cytokines is one 
particular way how neutrophils can modulate innate and adaptive immune responses. 
3.10 Neutrophil crosstalk with the innate immune system 
The first evidence that neutrophils play a regulatory role for DCs during microbial infection 
is dated back to 2003. Bennouna et al. could demonstrate that the supernatant from mouse 
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neutrophil cultures stimulated with Toxoplasma gondii induces the maturation of bone-
marrow-derived DCs in vitro, upregulates CD40 and CD86 and triggers the production of 
IL-12 and TNF in DCs 115. In line with this finding, splenic DCs from neutrophil depleted 
mice infected with Toxoplasma gondii show impaired IL-12 and TNF production 116. Studies 
with human neutrophils in vitro could show that they can induce maturation of monocyte-
derived DCs through TNF- α release 117 in a contact-dependent interaction involving CD18/ 
CEACAM1 and DC-SIGN 118. The neutrophil-DC interaction could be visualized at 
inflammatory sites in Crohn’s disease patients, where neutrophils frequently interact with 
DCs in the colonic mucosa 117. These findings show that neutrophils can modulate T-cell 
responses indirectly through DC activation and provide a cellular link between innate and 
adaptive immunity. In contrary, neutrophils also bear the potential of suppressive features 
on DCs, as shown by Maffia et al. They could demonstrate that neutrophil elastase 
decrease the allostimulatory ability of human monocyte-derived DCs by switching immature 
DCs into transforming growth factor (TGF-β)-secreting cells 119. Overall, there is 
accumulating evidence that neutrophils are capable to recruit and activate or inhibit DCs in 
vitro and in vivo 1,120. 
Neutrophils can also modulate natural killer (NK) cell survival, proliferation, cytotoxic 
activity and IFN-γ production by ROS production and granule protein secretion 121. 
Reciprocally, co-culture experiments with human neutrophils and NK cells ex vivo 21 or NK-
cell derived soluble factors (such as GM-CSF and IFN-γ) 20 promote neutrophil survival, 
expression of activation marker (CD11b, CD64, CD69), elevated ROS production and 
cytokine synthesis (e.g. heparin-binding EGF-like growth factor) 20,21,121.  
The molecular mechanism of prolonged neutrophil survival upon GM-CSF stimulation has 
been elucidated by several studies and involves Survivin, Bax, Bad and Mcl-1. Survivin is 
highly expressed in immature neutrophils, whereas strongly decreased in mature 
neutrophils 122. GM-CSF promotes mature neutrophils to re-express survivin to a higher 
extent, thus enhance inflammation and inhibit cell death 122. Another study has shown that 
GM-CSF reduces the expression of Bax, an important member of the bcl-2 family of pro-
apoptotic proteins 123, 124. Further, GM-CSF delays apoptosis via pro-apoptotic Bad 
phosphorylation at serine residue 99 125. Bad molecule is a paradigm showing activity upon 
dephosphorylation 126. Furthermore, GM-CSF supports Mcl-1 expression in neutrophils and 
high expression of Mcl-1 protein is correlated with prolonged neutrophil survival 127.  
The molecular role of IFN-γ on neutrophil survival has not been fully elaborated yet. One 
study has shown that IFN-γ synthesize and store tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) in neutrophils 128. TRAIL is able to interact with death receptors 
TRAIL1 and TRAIL2, both somehow linked in elimination of senescent neutrophils 129. 
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3.11 Neutrophil crosstalk with the adaptive immune system (T cells) 
Neutrophil interaction with T cells can result in T-cell suppression or T-cell activation, 
strongly dependent on the experimental conditions. Human co-culture experiments in vitro 
with neutrophils and T lymphocytes under non-inflammatory conditions reveal that 
neutrophils suppress CD4+ T-cell activation, proliferation and viability by the granule 
proteins arginase and calprotectin, but not MPO 130. Arginase release depletes extracellular 
L-arginine, an essential amino acid for T-cell activation, in the T-cell environment and 
downregulates CD3-zeta expression 131,132. Moreover, co-culturing neutrophils and T cells 
differentiates T-cell populations into a high fraction of IFN-γ and IL-17 producing T cells 
and decreases the percentage of IL-10 producing CD4+ T cells 130, highlighting a potential 
modulatory role of neutrophils in T-cell subset differentiation. Moreover, activated 
neutrophils produce ROS such as H2O2 that potently inhibit T-cell activation 133 and release 
anti-inflammatory cytokines such as IL-10 and TGF-β that have been shown to exert 
inhibitory activity on T cells 1.  
On the other hand, human neutrophils cultured with LPS and IFN-γ can recruit T helper subset 
17 (TH17) cells via release of chemokines (CCL2, CXCL9, CXCL10, CCL20) in vitro 134. Vice 
versa, regulatory T (TReg) cells can attract neutrophils by releasing IL-8, a potent neutrophil 
chemoattractant 135. Additionally, CD4+, CD8+ T cells and TH17 cells produce pro-
inflammatory cytokines such as GM-CSF, IFN-γ and TNF that modulate neutrophil survival 
and expression of activation markers in vitro 136, similarly like co-culture experiments with 
human neutrophils and NK cells ex vivo 20,21 (Fig. 2).   
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Recent evidence exists that neutrophils can migrate to lymph nodes following antigen 
capture at the periphery, as shown for Mycobacterium bovis Bacillus Calmette-Guerin 
vaccination 137, intracellular Toxoplasma gondii infection 138 and intradermal injection of 
modified vaccinia Ankara virus 139 and transport antigens to the site of T-cell activation. 
Similar to DC migration, the CC-chemokine receptor 7 plays an important role for 
neutrophil migration to the lymph nodes (LN) 140. Those LN- residing neutrophils are able to 
suppress B-cell- and CD4+ T-cell responses, but not the CD8+ T-cell response 141. 
Moreover, ex vivo injected antigen-pulsed neutrophils are shown to cross-prime naïve 
CD8+ T cells, strongly supporting a neutrophils-lymphocyte interaction in draining LN 140. 
The neutrophil-mediated immunosuppression is independent from ROS production, nitric 
oxide (NO) release or IL-10 production 141. In contrary, a study from Hampton et al. could 
show in a mouse model of local S. aureus skin infection that neutrophil re-localize to 
draining LN only when bacteria are present in the primary lesion. A process that is 
dependent on CD11b and CXCR4, but not CCR7. Moreover, LN- residing neutrophils 
augment B-cell-, CD4+- and CD8+ T-cell proliferation 142. Conclusively, neutrophils can 
interact with several different immune cell types in various niches in the body to modulate a 
huge repertoire of adaptive immune cell functions. 
  
Fig. 2: Interplay between neutrophils and 
T cells. Activated neutrophils release 
several chemokines and cytokines that 
mediate the recruitment of adaptive immune 
responses such as T helper 1 (TH1) cells, 
TH17 cells, CD8+ T cells, CD4+ T cells, gd T 
cells, regulatory T cells (TReg). CCL, CC-
chemokine ligand; CXCL, CXC-chemokine 
ligand; TNF, tumour necrosis factor; IFN, 
interferon; GM-CSF, granulocyte-
macrophage colony-stimulating factor. After 
Mantovani et al., Nature Reviews 
Immunology 2011. 
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3.11.1 Antigen presenting cells regulate adaptive T-cell immunity 
Professional antigen presenting cells (APCs) such as DCs, B cells and macrophages are 
pivotal for the induction of adaptive immune responses. Phenotypically, professional APCs 
constitutively express major histocompatibility complex (MHC) class II molecules and co-
stimulatory molecules such as CD80 and CD86. Functionally, professional APCs process 
and present antigens to CD4+ T cells thus triggering the adaptive immune system to 
respond to antigens in the periphery. Defects in this fine-tuned system have tremendous 
consequences. Patients suffering from MHC class II deficiency- also known as Bare 
lymphocyte syndrome (BLS) - suffer from severe and recurrent bacterial, viral, fungal and 
protozoan infections, leading to chronic diarrhea, malabsorption, growth retardation and 
death in early childhood 143- only due to the inability of CD4+ T cells to respond to antigens 
in the periphery. 
In recent years, the dogma that professional APCs are essential to induce adaptive 
immune responses has been challenged by the fact that- under certain conditions- atypical 
APCs can replace professional APCs (144,145, reviewed in 146). Atypical APCs are 
hematopoietic cell types (mast cells, basophils, eosinophils, innate lymphoid cells) with 
inducible MHC class II molecule expression and antigen presenting functions, which are 
often limited to specific immune environments. It is controversially discussed whether they 
can activate naïve CD4+ T cells in an antigen-specific manner. 
Whether neutrophils contribute as atypical APCs in infections is heavily debated 146 and the 
development and function of these atypical APC-like neutrophils in inflammation and 
infection have still to be elucidated. 
3.11.2 APC-like neutrophils in the human setting 
The first report describing de novo MHC class II molecule expression on human 
neutrophils after in vitro stimulation with IFN-γ has appeared in 1987 147. Furthermore, 
Gosselin et al. could demonstrate de novo MHC class II induction on mRNA and protein 
level after stimulation with GM-CSF 148. GM-CSF and IFN-γ stimulated human neutrophils 
activate superantigen-dependent T cell responses, but are not able to re-activate toxoid-
specific T cells 149. Opposite to this report, Iking-Konert et al. could demonstrate that MHC 
class II positive neutrophils express de novo co-stimulatory molecules such as CD86 and 
are able to induce proliferation of a tetanus-specific T-cell line in vitro 150. These in vitro 
findings are further supported by rare clinical trial reports where IFN-γ 151 and GM-CSF 152 
administration has similarly led to de novo MHC class II induction in human neutrophils, 
highlighting the in vivo relevance of this phenotype. 
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Moreover, two studies with rheumatoid arthritis patients have reported the presence of 
MHC class II+ and CD86+ neutrophils in synovial fluid, but not peripheral blood 153,154, 
whereas another study could show MHC class II positive and CD86+ neutrophils in synovial 
fluid as well as peripheral blood 155. These discrepancies can be partially explained by 
methodological variations. However, these findings support the idea that the local 
microenvironment (tissue, cell types, cytokines) shapes neutrophil phenotype. 
A recent report of APC-like phenotype in human neutrophils illustrates the crosstalk 
between neutrophils and mucosa-associated invariant T (MAIT) cells or γδ T cells and 
translates their findings to patients with severe sepsis. The authors speculate about 
plausible cytokine influence to shape APC-like phenotype in sepsis 156. However, it is 
unclear from that study whether neutrophils with APC-like phenotype can be found in 
peripheral blood during acute infection. Another study by Singhal et al. could identify a 
local subset of tumour-associated neutrophils (TANs) in stage I/II human lung cancer that 
shows granulocytes with APC-like phenotype. This particular TAN subset can cross-present 
tumour antigens and induces a functional anti-tumour T-cell response. Moreover, the 
development of these APC-like TANs from long-lived, immature bone marrow derived 
neutrophils requires tumour-derived factors GM-CSF and IFN-γ 157. However, a local 
synapse between APC-like neutrophils and T cells has not been shown by any group so far. 
To summarize, some cytokines show the potential to induce de novo MHC class II 
expression on neutrophils. It is unclear, which cytokine or cytokine combination is 
responsible to shape this APC-like phenotype. Moreover, the local relevance of APC-like 
neutrophils in vivo in respect to T-cell activation or T-cell suppression is still unknown. In 
general, the function of APC-like neutrophils in the development and manifestation of 
infectious and inflammatory diseases such as sepsis or rheumatoid arthritis remains 
undetermined. Furthermore, the understanding of cellular signalling pathways leading to 
APC-like phenotype and possible therapeutic approaches to interfere within this system are 
completely unknown.  
3.11.3 APC-like neutrophils in experimental animal models 
Compared to human research, there is limited knowledge available from mouse studies. 
Early studies could describe MHC class II expression (H-2 and I-A antigens) on peritoneal 
exudate (PEC)- derived neutrophils 158. One year later, the same authors describe 
exogenous antigen presentation capacity of those neutrophils to antigen-primed T cells 159, 
a finding to be supported and extended by Fitzgerald et al., who could show that PEC-
derived neutrophils present ovalbumin (OVA) to OVA-specific, naïve CD4+ T cells isolated 
from ovalbumin-specific (OT-II) T-cell receptor (TCR) transgenic mice 160.  
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In contrast, Abi Abdallah et al. could demonstrate that freshly purified PEC-derived neutrophils 
do not express MHC class II and CD86, but after co-culturing for 2 hours with naïve CD4+ T cells, 
neutrophils start to express de novo MHC class II, CD86 and slightly CD80. Furthermore, 
neutrophils need a direct T-cell contact to induce APC-like phenotype 161.  
However, all ex vivo systems are prone to artefacts and do not consider the local 
environment. In a mouse model of inflammatory bowel disease (chronic colitis), the authors 
could demonstrate APC-like phenotype in neutrophils in the colon (but not in peripheral 
blood, spleen or mesenteric lymph nodes). Moreover, colonic APC-like neutrophils could 
induce OVA-specific CD4+ T-cell proliferation ex vivo 162. In a mouse model of local S. 
aureus infection, it could be demonstrated that APC-like neutrophils are only induced in 
draining LN, but not in blood, spleen, non-draining LN or ear. Those LN-derived neutrophils 
induce CD4+ T-cell proliferation in vivo 142. However, the authors have used a potent 
depletion antibody to Ly6G+ to measure CD4+ T-cell proliferation in vivo, which eradicates 
all neutrophils instead of targeting selectively MHC class II+ neutrophils. Very recently, 
another study demonstrates that neutrophils sorted from vaccine-draining LN from rhesus 
macaques show expression of human leukocyte antigen- antigen D related (HLA-DR). 
Elevated HLA-DR expression requires the co-cultivation with autologous CD4+ T cells for 
30 hours ex vivo. Moreover, those APC-like neutrophils are able to present the vaccine 
antigen to autologous antigen-specific memory CD4+ T cell ex vivo 163. 
All reports highlight the role of local inflammation as driving force to shape APC-like 
phenotype in neutrophils. However, basic questions remain unanswered such as the role of 
cytokines to induce APC-like phenotype in vivo, cellular signalling pathways leading to 
APC-like induction and ultimately the functional and immunological consequences of the 
particular APC-like neutrophil subset, not total neutrophils, during the course of infection. 
3.12 The role of neutrophils in the pathology of sepsis 
3.12.1 Sepsis 
Sepsis is a heterogeneous host inflammatory response to severe, life-threatening infection 
with the manifestation of organ dysfunction 164. Sepsis imposes a detrimental global 
disease associated with high mortality and morbidity, especially in the elderly population 165. 
Recently, the World Health Organization has recognized sepsis as a global health priority 
and implemented strategies to reduce this fatal disease 166. The global incidence of sepsis 
is estimated up to 50 million annually 167 with estimated deaths up to 5.3 million 168. Current 
medical treatment options are vastly limited and there is a high unmet medical need for 
new therapies 169. 
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3.12.2 Pathophysiology and immune cell dysregulation 
Despite huge progress in the basic understanding of the pathophysiology of sepsis, the 
imbalances in the host immune system leading to sepsis are incompletely understood 170,171. 
Host immunity in sepsis is disturbed in a paradox way, involving excessive inflammation, 
immune suppression and an overall failure to return to normal homeostasis 168. Moreover, 
metabolic reprogramming in immune cells is an emerging concept in sepsis, too 172.  
Currently, there are two proposed controversial models of the host response in sepsis: the 
traditional model and the competing model. The traditional model describes the onset of 
sepsis with an acute hyperinflammatory phase over several days with systemic release of 
cytokines ("cytokine storm") 173 followed by a late immunosuppressive phase 
("immunoparalysis") with persistent severe lymphopenia ("T-cell exhaustion") 169,171,174,175. 
Innate immune cells, namely monocytes and neutrophils, trigger the hyperinflammatory 
phase by releasing high levels of proinflammatory cytokines (TNF, IL-1a, IL-6, IL-12, IL-18, 
IL-1b). Adaptive immune cells, namely the subset of innate activator B cells, produce IL-3, 
that further increases inflammation in a mouse model of sepsis 176. Moreover, IL-3 levels in 
human sepsis patients correlate with increased mortality 176. Taken together, this "cytokine 
storm" will lead to uncontrolled inflammation, fever, refractory shock, acidosis and 
hypercatabolism or even death 177. If the disease persists, patients will undergo the 
immunosuppressive phase ("immunoparalysis") 172,178. Deaths during the 
immunosuppressive phase can occur due to the failure to clear the primary infection or an 
enhanced susceptibility to secondary infections 165. This traditional model is supported by the 
findings that a decreased proinflammatory cytokine profile could be found in peripheral blood 
mononuclear cells and whole blood in the late phase of sepsis 179,180. Moreover, deaths in 
sepsis patients (post-mortem studies) in the late phase of sepsis are often accompanied by 
opportunistic infections, highlighting the broad defects in host immunity 181,182 associated with 
T-cell depletion and T-cell exhaustion 175. Interestingly, post mortem analysis of CD4+ T 
cells from sepsis patients reveal increased expression of programmed cell death 1 (PD1), 
while local macrophages and endothelial cells show increased expression of PD1 ligand 1. 
The inhibition of PD1-PD1 ligand 1 interaction in a septic mouse model results in improved 
survival 175, highlighting the PD1-PD1 ligand 1 interaction as a potential novel target for 
therapeutic approaches in sepsis.  
Immunoparalysis in sepsis is not only caused by T-cell exhaustion, but also DCs and 
macrophages. Both, DCs and blood derived monocytes show reduced HLA-DR expression 
in the late phase of sepsis 183,184, leading to insufficient adaptive immune response 
activation. Moreover, DCs produce elevated levels of anti-inflammatory IL-10 during sepsis, 
whereas monocytes show impaired capacity to produce pro-inflammatory cytokines (TNF, 
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IL-1a, IL-6, IL-12) upon stimulation in the late phase of sepsis 185. Moreover, enhanced 
anti-inflammatory cytokine secretion (IL-1RA, IL-10) in response to endotoxin is reported in 
monocytes, too 186. The exact mechanisms leading to immunoparalysis are not fully 
understood, but a recent report highlights broad defects in the energy metabolism of 
monocytes 172. Interestingly, IFN-γ therapy shows some partial restoration of 
immunometabolism and might be a potent therapeutic intervention in sepsis 172,187. 
Altogether, cytokine imbalances towards an anti-inflammatory state or pro-inflammatory 
state and reduced HLA-DR expression are worsening patient's prognosis during sepsis. Of 
note, the failure of many clinical trials with anti-inflammatory agents to treat patients with 
sepsis strongly supports the concept of immunoparalysis as an important 
pathophysiological characteristic in sepsis 188. However, the competing model agrees with 
the acute phase (hyperinflammatory phase), but the advocates postulate that an 
unremitting innate immune system inflammation persists and is ultimately responsible for 
organ injury and patient's death during the late phase of sepsis. This theory is supported by 
the fact that patients who have died from sepsis show longer duration and greater degree 
of organ injury, caused by innate immunity 189 (Fig. 3). 
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3.12.3 Neutrophils in sepsis 
Neutrophils as first line defense against invading pathogens play a major role to recognize, 
phagocytose and kill pathogens. Pathogen elimination is crucially dependent on neutrophil 
recruitment to the site of infection 5. Beside these classical effector functions, neutrophils 
contribute to the development of multiple organ failure in sepsis 190. Several studies 
observe that circulating neutrophil cell counts are abnormally high and neutrophil lifespan 
is prolonged in sepsis patients 191. Moreover, chemotactic activity seems to be reduced and 
consequently, neutrophil migration to the site of infection is impaired 191,192. A possible 
explanation for this migratory defect is the internalization of CXCR2 in circulating 
neutrophils from mice or patients with severe sepsis 193-195. Furthermore, IL-17 signaling 
could be shown to be crucial for recruitment of neutrophils to the site of infection during 
sepsis 196. Interestingly, neutrophils isolated from sepsis patients show reduced migratory 
capacity ex vivo, linking to the clinical observation of patient survival: Survivors show 
higher neutrophil migration compared to non-survivors 197. The migratory defect could be 
partially restored by IL-33 treatment 198.  
Fig. 3: Competing theories of the host 
immune response in sepsis. Theory 1: 
Early deaths in sepsis are due to the 
overwhelming cytokine-driven 
inflammation, whereas late deaths are 
explained by persistent 
immunosuppressive features and 
recurrent infections. Theory 2: In 
agreement with theory 1, early deaths in 
sepsis are explained by overwhelming 
cytokine-driven inflammation processes, 
whereas late deaths are due to 
inflammation-driven organ injury events. 
After Hotchkiss et al., Nature Reviews 
Immunology 2013. 
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NETosis is a highly efficient host defense mechanism in pathogen control 64. Interestingly, 
NETosis in circulation is increased in sepsis patients, ultimately leading to organ 
dysfunction 199, in agreement with a previous report in a mouse model of endotoxemia that 
has shown platelet TLR4-mediated NETosis in sepsis 200. NETosis formation occurs by the 
exposure of human neutrophils to plasma from septic patients 200 and by direct pathogen 
contact 201 (Fig. 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recent findings postulate neutrophil plasticity as a driving force in sepsis, ultimately 
leading to novel neutrophil subsets (such as PMN-myeloid-derived suppressor cells, short 
PMN-MDSC) with immunosuppressive features 202,203. Human studies with sepsis depicts 
increased numbers of PMN-MDSCs, dominating in gram-positive cases 204,205. The PMN-
MDSC subset is associated with adverse outcome 206. Moreover, it is shown in 
experimental mouse models of polymicrobial sepsis that MDSCs induce T-cell suppression, 
TH2 polarization and reduce T-cell cytokine production (such as IFN-γ and IL-2) 202. Another 
report could show that specific neutrophil subsets produce large amounts of IL-10 207 and 
they have inhibitory effects on T-cell proliferation 208.  Since there is a correlation between 
gradual increase of MDSC frequency and the onset of sepsis, it is speculated that MDSCs 
exert an immunosuppressive effect on adaptive immunity, similarly to the situation 
observed in cancer 205. So far, it is still unclear whether PMN-MDSCs influence the 
induction of various CD4+ T-cell subpopulations (e.g. TReg cells) or contribute to T-cell 
exhaustion during the immunosuppressive phase in sepsis. Moreover, neutrophils and 
PMN-MDSCs share common cell markers and are morphologically identical, thus it is a 
substantial problem to distinguish both cell types from each other 3.  
 
Fig. 4: Impact of sepsis on neutrophils in sepsis. 
Abnormal neutrophil counts with elevated levels of 
immature cells and decreased apoptosis. Neutrophil 
functionality in sepsis is impaired by decreased ROS 
production, decreased nitric oxide release and 
reduced expression of adhesion markers. After 
Hotchkiss et al., Nature Reviews Immunology 2013. 
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In conclusion, there are many ambiguities in the understanding of the role of PMN-MDSCs 
in sepsis and future research will hopefully address these important questions. 
There are some reports supporting a role of atypical APC-like neutrophils in sepsis 209, 
especially in GM-CSF- rich environments 146. Davey et al. could find an APC-like 
phenotype in neutrophils in acute human sepsis (increased levels of CD86, CD64 and 
CD40), a phenotype that can be induced by unconventional T cells 210. Delano et al. could 
identify an immature Gr-1+/ CD11b+ population in a murine mouse model of polymicrobial 
sepsis, which contributes to sepsis-induced T-cell suppression and TH2 polarization 202. 
Nevertheless, it is unclear how relevant those APC-like neutrophils in vivo are and how 
they contribute in the pathophysiology of sepsis. 
Another mechanism by which neutrophils might support T-cell exhaustion in sepsis is through 
programmed cell death ligand 1 (PD-L1) 211. Neutrophils isolated from sepsis patients express 
the surface molecule PD-L1, a potent inducer of T-cell exhaustion and apoptosis 212. Moreover, 
PD-L1 expression level on neutrophils is positively correlated with sepsis severity 213,214 and 
negatively correlated with the monocyte HLA-DR expression level 212. It is unclear whether 
IFN-g 215, GM-CSF 216 or the combination 217 induce PD-L1 expression on neutrophils. 
However, the PD-1– PD-L1 axis is thought to be an important mechanism in immune 
suppression in sepsis patients 169,218 and PD1-PD-L1 inhibition after the induction of sepsis 
improves survival in mice 219.  
To summarize, both competing sepsis models agree that innate immunity, namely 
neutrophils and monocytes, plays a crucial role in the orchestration of aberrant adaptive 
immune responses in sepsis. However, the impact of human neutrophils and monocytes 
during septic immune responses are incompletely understood, mostly limited to a 
descriptive design and lacking in a systematic analysis 191, whereas animal studies are 
limited in profound reflection of human sepsis 169,191. Of note, the role of neutrophils during 
sepsis is sparsely described and novel approaches to elaborate the role of neutrophils in 
sepsis are urgently needed. A systematic understanding of the inflammatory, dysregulated 
immune response in human sepsis supported with adequate sepsis mouse models will 
have crucial implications for the development of new therapeutic approaches in sepsis.  
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4 Aim of the thesis 
Pathogen clearance in infectious diseases strongly depends on protective innate and 
adaptive host immunity. Past research has focused on the important role of neutrophils as 
first line defense in innate immunity against pathogens. Recent reports highlight that the 
immunological function of neutrophils in inflammation is highly versatile and goes far 
beyond simple pathogen destruction. However, the diverse role of neutrophils under 
inflammatory conditions in infectious diseases and their contribution in mediating adaptive 
immune responses has been largely neglected so far. To understand infectious diseases in 
more details, it is of highest interest to understand neutrophil biology under inflammatory 
conditions in the host. My aim was to investigate the diversity of neutrophil biology 
encountering pathogenic microorganisms that cause infectious diseases. To achieve this 
aim, I used human neutrophils from healthy individuals and from patients suffering from 
various infectious diseases and immunological disorders, respectively, in combination with 
a mouse model of Salmonella infection with the help of techniques such as flow cytometry, 
RT-PCR and proteomics to reveal the so far underestimated diversity in neutrophil function 
in infectious diseases. 
 
My main questions are the following: 
a. How do neutrophils protect against invading pathogens? 
b. What are the versatile neutrophil functions in inflammation/ infection? 
c. How do neutrophils crosstalk with other immune cells? 
By answering these questions, I would like to show that infectious disease control implies a 
diverse neutrophil functionality ranging from simple foot soldiers to versatile commanders 
of immunity. 
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5 Results 
5.1 Myeloperoxidase targets oxidative host attacks to Salmonella and prevents 
collateral tissue damage 
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5.2.1 Abstract/ Summary  
Sepsis is a detrimental disease manifested as dysregulated host immunity upon infection. 
Despite the unambiguous involvement of neutrophils in this fatal disease, there are very 
limited data about the molecular signaling mechanisms, phenotype and function in human 
neutrophils in sepsis. Here, we systematically elaborated the role of neutrophils in the 
inflammatory phase of sepsis to understand the aberrant neutrophil immune response. By 
using a large-scale proteomics and flow cytometry approach, we identified an antigen-
presenting cell (APC)-like phenotype in neutrophils with major histocompatibility complex 
(MHC) class II molecule expression. These APC-like neutrophils could be induced by pro-
inflammatory cytokines such as granulocyte-macrophage colony-stimulating factor (GM-
CSF) and interferon-g (IFN-g) and were capable to activate T-cell clones upon antigen 
presentation. GM-CSF-stimulated neutrophils reorganized a complex network of 
phosphoproteins which in turn led to the activation of three major signaling pathways, the 
Janus kinase- signal transducer and activator of transcription (JAK-STAT), the mitogen-
activated protein kinase (MAPK) and the phosphoinositide 3-kinase (PI3K)-Akt-mechanistic 
target of rapamycin (mTOR) pathways. The overrepresented MAPK kinase activity and the 
central JAK1/2 kinase orchestrated the downstream protein phosphorylation cascade, 
leading to the formation of the MHC class II enhanceosome via cAMP response element-
binding protein 1 (CREB1) phosphorylation and class II major histocompatibility complex 
transactivator (CIITA) induction. In a mouse model of systemic salmonellosis, we could 
demonstrate the presence of APC-like neutrophils in vivo. These data show that neutrophil 
immune cell function in sepsis is highly versatile and goes far beyond simple pathogen 
destruction. 
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5.2.2 Introduction 
Sepsis is the host inflammatory response to severe, life-threatening infections with the 
manifestation of organ dysfunction 164. Sepsis imposes a detrimental global disease 
associated with high mortality and morbidity 165. The global incidence is estimated up to 50 
million annually 167, with estimated deaths up to 5.3 million 168. Recently, the World Health 
Organization has recognized sepsis as a global health priority and implemented strategies 
to reduce this fatal disease 166. Current medical treatment options are vastly limited and 
there is a high unmet medical need globally for new therapies 169. 
Despite huge progress in the basic understanding of the pathophysiology of sepsis, the 
imbalances in the host immune system leading to sepsis are incompletely understood 170,171. 
Host immunity in sepsis is disturbed in a paradox way, involving excessive inflammation, 
followed by immune suppression and an overall failure to return to normal immune 
homeostasis 168. Metabolic reprogramming in immune cells raising aberrant immune 
responses is an emerging concept in sepsis 172.  
Neutrophils as first line defense against invading pathogens play an explicit role to 
recognize, phagocytose and kill pathogens in sepsis. Pathogen elimination is crucially 
dependent on neutrophil recruitment to the site of infection 5. Beside those beneficial 
neutrophil responses, neutrophils can contribute to the development of multiple organ 
failure in sepsis 190, most likely by aberrant regulation of NETosis 199. Therefore, the precise 
orchestration of neutrophil immune responses is indispensable for a good outcome in 
sepsis. 
Several studies have observed that circulating neutrophil cell counts are abnormally high 
and neutrophil lifespan is prolonged in sepsis 191. Moreover, chemotactic activity seems to 
be reduced and neutrophil migration to the site of infection is impaired 191,192. Recently, 
there are some rare reports supporting a role of atypical antigen-presenting cell (APC)-like 
neutrophils in sepsis 209. Davey et al. found an APC-like phenotype of circulating 
neutrophils in acute human sepsis with increased levels of APC-associated molecules 
(CD86, CD64 and CD40), a phenotype that can be induced by unconventional T cells in 
vitro 210. Delano et al. identified an immature Gr-1+/ CD11b+ population in a murine mouse 
model of polymicrobial sepsis, which contributed to sepsis-induced T-cell suppression and 
TH2 polarization 202. Nevertheless, it is largely unknown how these APC-like neutrophils 
contribute in the pathophysiology of sepsis and which signaling mechanisms lead to an 
APC-like neutrophil phenotype. Moreover, the impact of neutrophils during septic immune 
responses are incompletely understood, mostly limited to a descriptive design and lack in a 
systematic analysis 191.  
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Novel approaches to elaborate the role of neutrophils in sepsis are urgently needed and a 
systematic understanding of the inflammatory, dysregulated immune response will have 
crucial implications for the development of new therapeutic approaches in sepsis. The 
purpose of the study was to characterize the phenotype, function and signaling 
mechanisms in neutrophils in the inflammatory phase of sepsis.  
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5.2.3 Research highlights 
o This report systematically elaborated the role of human neutrophils in the 
inflammatory phase of sepsis to understand the aberrant immunological neutrophil 
response in this fatal disease. 
o We could demonstrate with a proteomics approach and flow cytometry that human 
neutrophils in sepsis within a pro-inflammatory milieu are shifting into a novel APC-
like phenotype with elevated MHC class I and de novo induced MHC class II 
molecule expression. 
o MHC class I and MHC class II expression on human neutrophils could be induced 
by pro-inflammatory cytokines GM-CSF (for MHC class II) and IFN-g (for MHC class 
I and MHC class II) after 48h in culture and were capable to activate T-cell clones 
upon peptide stimulation.   
o GM-CSF stimulation in neutrophils alters the phosphorylation of a complex network 
of proteins involved in 3 major signaling pathways, the JAK-STAT, the MAPK and 
the PI3K-Akt-mTOR pathways, with overrepresented MAPK kinase activity and a 
central JAK1/2 kinase orchestrating the broad downstream protein phosphorylation. 
Moreover, we could link GM-CSF signaling to the formation of the MHC class II 
enhanceosome via CREB1 phosphorylation at serine 133. 
o We could demonstrate that the MAPK-p38-MSK1-CREB1 signaling cascade 
contributes to de novo MHC class II induction in neutrophils and the MHC class II 
transactivator CIITA is highly expressed after 4h stimulation with GM-CSF in vitro, 
in agreement with experimental data for IFN-g-stimulated, non-constitutive MHC 
class II expression in human vascular endothelial cells and macrophages. 
o In a mouse model of systemic salmonellosis that mimics important aspects of 
human typhoid fever, we confirmed the presence of APC-like neutrophils in vivo, 
strongly supporting the results found in human sepsis. 
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5.2.4 Results  
Neutrophils mimic APC-like phenotype in patients with sepsis 
Neutrophils from 34 sepsis patients and healthy controls, matched for age (74 years versus 
76 years; N=23,10; P>0.05; Fig. S1A) and body mass index (25.3 kg/m2 versus 25.5 kg/m2; 
N=18,10; P>0.05; Fig. S1B), were investigated. Baseline characteristics are listed in Table 
1. In accordance with literature165,191,220, we found significantly increased absolute numbers 
of circulating neutrophils and decreased reactive oxygen species (ROS) production in 
response to bacterial and fungal stimuli in sepsis patients compared to healthy controls (74 
x 106 cells versus 41.1 x 106 cells in total per 15ml blood; N=21,10; P<0.01; Fig. 1A, Fig. 
S1D). Neutrophils viability was 99% in both, healthy controls and sepsis patients (Fig. 
S1C). Moreover, sepsis patients showed a significantly higher neutrophils-to-lymphocyte 
ratio (NLR, Fig. S1E), an inflammation marker and potential predictor for poor disease 
outcome 221. In a systematic proteomics approach, we identified in total 2204 peptides with 
mass spectrometry, of these 380 peptides were significantly changed in sepsis (Fig. 1B, 
317 peptides upregulated, 63 downregulated, p-value < 0.02). Metacore Enriched Pathway 
Analysis identified antigen presentation by MHC class I and II as strongly enriched in 
patients with sepsis (Antigen presentation by MHC class I, p-value = 10-9; Antigen 
presentation by MHC class I: Cross-presentation, p-value = 10-6; Antigen presentation by 
MHC class II, p-value = 10-2; Fig. 1C, Fig. S1F). GO Enrichment Analysis of Processes and 
Molecular Functions confirmed antigen processing and presentation as highly enriched in 
sepsis (Fig. S1G; Fig. S1H). 
We identified 21 proteins involved in antigen presentation by MHC class I and II that were 
significantly changed upon sepsis (Fig. 1D, threshold set at p-value < 0.02, ratio cut off 
(log2) > 0.6, and Fig. S1I). We identified three strongly upregulated MHC class I proteins 
(1B42, 1B73, 1B45), five endoplasmic reticulum-to-golgi peptides (SC23A, RB27A, 
HYOU1, SC24D, VAMP3), one molecule in the TAP complex (TAP1), one aminopeptidase 
(ERAP1), tapasin (TPSN), calreticulin (CALR), one protein of the 26S proteasome complex 
(PSD12) and two proteins of the 20S core proteasome complex (PSB2, PSB4), all 
contributing to antigen processing and presentation by MHC class I and MHC class II 
molecules to the adaptive immune system 222-224 (Fig. 1E, Fig. S1J). These data strongly 
suggested that neutrophils might have acquired antigen presentation capacity in sepsis. To 
verify the proteomics data, we elaborated surface expression of MHC class I and II on 
neutrophils with flow cytometry. Surface staining for HLA-A, -B, -C confirmed a 1.57-fold 
increase in MHC class I levels (MFIsepsis = 35304, MFIcontrol = 22418, Fig. 1F) and de novo 
induction of MHC class II expression (0.93% and 4.11% HLA-DR/ -DP/ -DQ+ PMN in 
controls and sepsis patients, respectively, Fig. 1G) on neutrophils in sepsis. Additionally, 
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increased surface expression of single HLA-DR and the invariant chain Li (CD74) strongly 
supported de novo MHC class II induction in sepsis (Fig. S1K). 
Since sepsis is considered to be a heterogeneous, inflammatory host response to an 
infection 165,168, we analyzed blood serum samples from patients and controls for their 
particular inflammatory cytokine signature. Interleukin-6 (IL-6), granulocyte-macrophage 
colony-stimulating factor (GM-CSF), interferon-gamma (IFN-g), monocyte chemotactic 
protein 1 (MCP-1, also known as CCL2), and interleukin-18 (IL-18) were significantly elevated 
in plasma samples from sepsis patients (Fig. 1H), whereas interleukin-8 (IL-8), interleukin-
1beta (IL-1b), interleukin-17 (IL-17A), interleukin-23 (IL-23), interleukin-10 (IL-10), tumor 
necrosis factor- alpha (TNF-a) were not changed and interleukin-12 (IL-12) and interleukin-
33 (IL-33) were not detectable (below standard curve range) (Fig S1L).  
Taken together, we could demonstrate with a large-scale proteomics approach and flow 
cytometry that human neutrophils in sepsis are modulated to APC-like phenotype with 
elevated MHC class I and de novo induced MHC class II expression. Moreover, neutrophils 
in sepsis are in a cytokine-rich, pro-inflammatory environment with high levels of IL-6, GM-
CSF, IFN-g, MCP-1 and IL-18.  
 
GM-CSF and IFN-g induce APC-like phenotype in human neutrophils in vitro, reduce 
neutrophil apoptosis and stimulate T-cell clones upon antigen presentation 
Next, we investigated the capability of those cytokines with increased levels in sepsis to 
induce APC-like phenotype in human neutrophils. IFN-g was able to upregulate HLA-A, -B, 
-C on neutrophil surface after 24h of cultivation (Fig. S2A, top; mRNA level for HLA-B and 
B2M in Fig. S2A, bottom). GM-CSF and IFN-g were able to induce de novo HLA-DR/ -DP/- 
DQ expression after 48 hours of incubation, whereas IL-6 and IL-18 had no effect on MHC 
class I or II expression (Fig. 2A-C). In parallel, we found that GM-CSF and IFN-g prolonged 
neutrophil survival (Fig. 2A, upper panel and Fig. S2B). To clarify whether de novo HLA-
DR/ -DP/- DQ expression is not only the consequence from prolonged neutrophil survival, 
we used a low-dose, effective Pan-Caspase inhibitor q.OPh 225 (Fig. S2E) to reduce neutrophil 
apoptosis in vitro (Fig. 2A-C, Fig. S2A-C). The Caspase inhibitor q.OPh reduced the extrinsic 
(via Caspase-8, Caspase-3) and intrinsic Caspase (via Caspase-9, Caspase-3)-mediated cell 
death pathway (Fig. S2D), but did neither affect de novo HLA-DR/ -DP/- DQ expression nor 
HLA-A, -B, -C induction on human neutrophils (Fig. 2B, Fig. S2A). De novo induction of 
HLA-DR and CD74 (Li) by GM-CSF and IFN-g stimulation was further confirmed on RNA 
level (Fig. 2E). 
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Previous reports described an APC-like phenotype mostly in immature neutrophil 
populations 157. To determine if mature neutrophils are able to develop an APC-like 
phenotype, we visualized single cells by Image Stream X. The HLA-DR/ -DP/- DQ molecule 
co-localizes with surface marker CD66b (Fig. 2D). Notably, HLA-DR/ -DP/- DQ+ neutrophils 
had segmented nuclei morphology, indicating that neutrophils expressing APC-like 
molecules are mature 226 (Fig. 2D, gating strategy for Image Stream X in Fig. S2F, higher 
magnification in Fig. 2F). 
Next, we wanted to know whether HLA-DR+ neutrophils are capable of antigen 
presentation to an autologous peptide-specific CD4+ T-cell clone in vitro. For that reason, 
we stimulated neutrophils with GM-CSF and IFN-γ for 48 hours, pulsed them with a specific 
peptide and measured CD4+ T-cell activation by intracellular cytokine staining for IFN-γ and 
TNF-α 227 (Fig. 2G, middle and right panel). Autologous dendritic cells (DCs) were used as 
a positive control. Although our data show that APC-like neutrophils are capable to present 
peptides and activate CD4+ T cells in vitro, it is still a minor effect compared to professional 
APCs such as DCs.  
Together, these data show that the pro-inflammatory cytokines GM-CSF and IFN-g can 
reduce neutrophil apoptosis in vitro and are able to induce de novo expression of MHC 
class II on mature neutrophils after 48h in culture (Fig. S2G). Moreover, these cytokine-
primed APC-like neutrophils are able to induce autologous CD4+ T-cell activation in vitro. 
 
GM-CSF signaling leads to the activation of JAK-STAT, MAPK p38 and Akt- mTOR 
signaling pathways and phosphorylation of transcription factor CREB1  
Next, we wondered which signaling pathways are responsible for cytokine-induced MHC class 
II expression on neutrophils. Since the IFN-g signaling pathway associated with MHC class II 
induction is well described in human vascular endothelial cells and macrophages 143,228, we 
focused on GM-CSF-induced MHC class II expression. Previous studies have already 
shown that GM-CSF signaling in neutrophils affects diverse cellular processes such as 
survival, proliferation, differentiation and ROS production 229. For that reason, we used a 
label-free quantitative phosphoproteomics strategy and analyzed phosphorylation by liquid 
chromatography-tandem mass spectrometry, as previously described 230 (Fig. 3A). In 
human neutrophils stimulated in vitro for 30 minutes with GM-CSF, we detected 3579 
phosphopeptides. 858 phosphopeptides showed significantly changed phosphorylation 
(n=466) or desphosphorylation (n=392) status (Fig. S3A-C, q-value < 0.05).  
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The majority of significant phosphorylation and dephosphorylation events were identified 
on serine and threonine residues (Fig. S3A). As a control, neutrophil stimulation with GM-
CSF induced optimal STAT5 phosphorylation after 30 minutes in vitro (Fig. S3D). The 
phosphoproteomics data set revealed the induction of MAPK signaling, JAK-STAT and 
PI3K-Akt-mTOR signaling pathways after GM-CSF stimulation in vitro (Fig. 3B), in 
agreement with literature 231. We confirmed the involvement of those 3 identified pathways 
by flow cytometry using phospho-STAT5 (pY694), phospho-mTOR (pS2448), phospho-Akt 
(pS473), and phospho-p38 (pT180/pY182) (Fig. 3D) and pharmacological inhibition to 
JAK1/2 (Ruxolitinib), PDK-1 (BX-745), Akt (MK-2206) and mTORC1/2 (PP242). JAK1/2 
inhibition with Ruxolitinib at non-toxic concentrations (data not shown) led to full inhibition 
of STAT5, mTOR, Akt and p38 phosphorylation in human neutrophils (Fig. 3E). To identify 
overrepresented phosphorylation motifs in the phosphoproteome, we applied the motif 
extraction by Motif-X algorithm 232,233. We found ten distinctive motif sequences with central 
serine phosphorylation (Fig. 3C, left, q-value < 0.05), including the motifs SP, RXXS, PXSP, 
RXS, and RXRXXS. By using an experimentally verified kinase prediction tool collecting 
phosphorylation sites from PhosphoELM and SwissProt (RegPhos 1.0, www.regphos-
mbc.nctu.edu.tw 234) and using extensive literature research, we predicted MAPK signaling as 
predominantly represented (JNK, p38, ERK signaling for SP motif 234; RSKs, MSK1/2 for RXXS 
motif 230,235; MEK/ ERK2 signaling for PXSP motif 235,236,237), whereas Akt (or AGC kinase family 
for RXRXXS 230) signaling was less prominent (Fig. 3C).  
We further identified an important candidate linking GM-CSF signaling to APC-like 
phenotype, the cyclic AMP response element-binding protein1 (CREB1) 143,238 (Fig. 3B). 
CREB1 phosphorylation is an essential part in the formation of the MHC class II 
enhanceosome, consequently leading to the induction of MHC class II gene expression 239. 
Taken together, these results show that GM-CSF stimulation in neutrophils alters the 
phosphorylation of a complex network of proteins involved in 3 major signaling pathways, 
the JAK-STAT, the MAPK and the PI3K-Akt-mTOR pathways (Fig. S3E), with 
overrepresented MAPK kinase activity and a central JAK1/2 kinase orchestrating the broad 
downstream protein phosphorylation. Moreover, we could link GM-CSF signaling to the 
potential formation of the MHC class II enhanceosome via CREB1 phosphorylation at 
serine 133.  
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Targeting the MHC class II enhanceosome in human neutrophils  
Next, we aimed to identify the responsible kinase for CREB1 phosphorylation at residue Ser133 
in neutrophils. Potential candidates for CREB1 phosphorylation are the kinases mitogen- and 
stress-activated protein kinase-1 (MSK1), p90 ribosomal S6 kinase (pp90RSK), Akt and protein 
kinase A (PKA). Using pharmacological inhibitors specifically targeting these kinases, we could 
demonstrate that only MSK1 inhibition significantly reduces CREB1 phosphorylation (Fig. 4A, 
right; representative example for CREB1 phosphorylation at Ser133, Fig. 4A, left; Fig. S4A). 
Again, JAK1/2 inhibition led to the full inhibition of CREB1 phosphorylation, in agreement with our 
previous finding that JAK 1/2 is not only necessary for the JAK-STAT pathway, but also involved 
in the MAPK and the PI3K-Akt-mTOR signaling pathways (Fig. 3E). 
Next, we investigated the link of CREB1 phosphorylation with the induction of de novo MHC 
class II expression in neutrophils. Pre-treatment with various, non-toxic concentrations of 
CREB1-CBP protein interaction inhibitor 240 and consecutive stimulation with GM-CSF for 48h 
showed a dose-dependent reduction up to 70% in HLA-DR/ -DP/ -DQ surface expression on 
neutrophils (Representative example, Fig. 4D, left; Summary in Fig. 4D, right), whereas CREB1 
on a transcriptional level was not affected by GM-CSF stimulation (Fig. 4C). Secondly, 
pharmacological inhibitors to JAK1/2, p38 and MSK1, but not to MEK1/2 and ERK, inhibited 
HLA-DR/ -DP/ -DQ surface expression on neutrophils (Fig. 4E), strongly supporting the role of 
MAPK-p38-MSK1-CREB1 signaling axis as driver for de novo MHC class II induction on 
neutrophils. 
In addition to CREB1 phosphorylation 239, the transcriptional control of MHC class II gene 
expression is tightly regulated in cell types such as human endothelial cells and monocytes-
macrophages by another 3 key factors (reviewed in 143), namely the MHC class II transactivator 
CIITA 241,242, NFY 243 and the RFX complex (composed of RFX5 244, RFXAP 245 and RFXANK246. 
Therefore, we investigated whether de novo MHC class II expression in neutrophils uses a 
similar mechanism. We tested CIITA mRNA levels 4h, 24h and 48h after GM-CSF stimulation 
and found a 100-fold CIITA upregulation after 4h, with a gradual decrease over time (Fig. 4B). 
CIITA induction could be fully blocked using a JAK1/2 inhibitor (Fig. S4B), again accentuating the 
central role of JAK1/2 signaling for MHC class II induction in neutrophils. However, NFYa, 
RFXank and CREB mRNA levels were not affected by GM-CSF stimulation (Fig. 4C), in 
agreement with literature that stresses CIITA as the master transcriptional regulator of the MHC 
class II enhanceosome 143,242. To summarize, we could demonstrate that GM-CSF-induced de 
novo expression of MHC class II on neutrophils is mediated by the same MHC class II 
enhanceosome that also regulates IFN-g-induced, non-constitutive MHC class II expression in 
human vascular endothelial cells and macrophages 228.  
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GM-CSF-induced MHC class II induction is mediated by a MAPK-p38-MSK1-CREB1 signaling 
cascade and the MHC class II transactivator CIITA in a strictly JAK1/2 kinase-dependent manner 
(Fig. 4F). 
 
Induction of APC-like neutrophils in a systemic Salmonella mouse model mimicking 
human typhoid fever 
To investigate the relevance of APC-like neutrophils in vivo, we used a well-established 
mouse model of systemic salmonellosis 247,248. To demonstrate the homology of this model 
to human sepsis, we compared the proteome data sets obtained from splenic neutrophils 
of mice infected with Salmonella enterica serovar Typhimurium with the proteome data sets 
from human sepsis patients. Splenic proteome analysis from sorted PMN (CD11b+, Ly6CInt, 
Ly6G+) of infected mice compared to uninfected mice at day 4 post infection (Fig. S5A) 
identified 2223 peptides in total, of which 595 peptides were significantly changed upon 
Salmonella infection (Fig. S5B, 503 peptides upregulated, 92 downregulated, p-value < 
0.03, fold change > 1.5). Comparable to the data obtained in sepsis patients, the analysis 
revealed a significant change in antigen processing and presentation pathways in infected 
mice (Fig. 5E; Fig. S5B-E). Comparison of the human and murine data sets in terms of 
common differential protein expression by using one-to-one orthologous homology 
information from the Ensembl database 249-251 identified in total 1157 orthologous proteins 
in humans and mice (Fig. 5F). 52 orthologous proteins were differentially expressed in both 
species during infection, most of them are linked to antigen presentation and processing 
pathways (FDR<0.05; Fig. S5F), clearly indicating that the systemic salmonellosis model is 
ideally suited to investigate APC-like neutrophils in a mouse model. 
Next, we investigated the kinetics of neutrophil MHC class II induction during the course of 
infection in different organs, such as blood, bone marrow, spleen and liver. In the systemic 
Salmonella infection model, bacteria replicate early in spleen and liver and disseminate to the 
blood and bone marrow during the peak of infection at day 4 (Fig 5D). Interestingly, APC-like 
neutrophils (CD45+/ CD11b+/ Ly6G+/ Ly6Cint) expressing MHC class II were present in all 
organs starting 2 days after infection and MHC class II expression did not directly correlate 
with bacterial load (Fig. 5C, splenic example dot plot in Fig. 5B). 
In conclusion, these in vivo data substantiate the suitability of the systemic salmonellosis 
mouse model as appropriate model to study bacterial sepsis and confirm the induction of 
APC-like neutrophils during sepsis, revealing the vast heterogeneity and diversity of 
neutrophils under inflammatory conditions. 
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5.2.5 Discussion 
Neutrophils in sepsis are believed to execute direct pathogen killing. In this study, we 
identified a subset of neutrophils with antigen-presenting properties during the 
hyperinflammatory phase of sepsis. These MHC class II+ neutrophils can be induced by 
GM-CSF and IFN-g via the formation of the MHC class II enhanceosome and are able to 
present antigens and activate antigen-specific T-cell clones. Furthermore, these findings 
could be confirmed in a mouse model of systemic Salmonella infection, where this APC-
like neutrophil subset already appears after 2 days of infection with cellular protein 
changes involved in antigen processing and presentation. Thus, the role of neutrophils in 
sepsis seems to go beyond direct pathogen killing mechanisms and is pointing towards 
immunoregulatory functions in sepsis. 
Moderate levels of MHC class II on neutrophils have been previously identified in human 
autoimmune diseases such as Wegener’s granulomatosis 252,253 and rheumatoid arthritis 153. 
However, it is controversially discussed whether similar mechanisms exist in the context of 
bacterial infections. In our study, we found that during the early phase of sepsis, 
neutrophils acquire antigen-presenting cell characteristics. Simultaneously high levels of 
IFN-g and GM-CSF are detected in plasma of sepsis patients. This is in line with previous 
reports 148,252,254,255 that show that both cytokines GM-CSF and IFN-g can induce de novo 
MHC class II transcription and surface expression on human neutrophils. Thus, we believe 
that the inflammatory conditions and not bacterial infection per se triggers the induction of 
APC-like neutrophils in sepsis. 
While previous work has focused on proteomic changes of secreted proteins from ex vivo 
stimulated neutrophils with cytoB/fMLF from sepsis patients 256, this is to our knowledge the 
first study investigating comprehensively the proteomic changes in neutrophils from human 
and mouse sepsis. Despite patient heterogeneity, individual medical treatment and 
differences among species, the human neutrophil proteome in sepsis shares 36% of 
homologous protein regulation with the mouse neutrophil proteome in gram-negative 
infection (FDR < 0.05). Most of the identified proteins are linked to the cellular machinery 
involved in antigen presentation and processing.  
Our work adds to a recent study showing that MHC class II and costimulatory molecules 
are induced in the presence of antigen and antigen-specific memory CD4+ T cells 163. Most 
likely, antigen-specific memory CD4+ T-cell derived cytokines such as GM-CSF and IFN-g 
induce the observed MHC class II expression on neutrophils in vitro, as we demonstrated 
in our study. Supporting this idea, we could observe that antigen-specific CD4+ T cell 
clones produce large amounts of GM-CSF and IFN-g upon activation 257.  
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However, it should be noted that all in vitro studies (including our group) have used high 
cytokine levels at non-physiological levels (ranging from 1-100 ng/ml) to induce APC-like 
phenotype. It remains speculative whether neutrophils in vivo encounter these somehow 
artificial conditions. Therefore, it would be relevant to measure local, heterogeneous 
cytokine concentration gradients among tissues and organs in vivo.  
Among GM-CSF, IFN-g and other cytokines 258, high levels of IL-3, a close family member 
of GM-CSF 259, has been recently linked to high mortality in human sepsis. The authors 
have showed that IL-3 potentiates acute inflammation and contributes majorly to the 
observed “cytokine storm” in the inflammatory phase of sepsis 176. However, it is unclear 
from that study whether IL-3 also induces APC-like neutrophil phenotype and whether 
APC-like neutrophils contribute to the observed cytokine storm. Future studies might clarify 
this issue.  
We further investigated signaling mechanisms that control de novo MHC class II 
expression in neutrophils. Previous studies could show that the control of de novo MHC 
class II expression is tightly regulated by several key factors (reviewed in 143), namely the 
MHC class II transactivator CIITA 241,242, CREB1 239, NFY 243 and the RFX complex 
(composed of RFX5 244, RFXAP 245 and RFXANK246) and that genetic deficiencies in those 
key factors can cause severe pathologies such Bare Lymphocyte syndrome (BLS) 241 and 
lymphoid cancers 260. However, since these studies on de novo MHC class II induction 
have been restricted to the IFN-g signaling pathway in human vascular endothelial cells 
and macrophages 143,228, it is vastly unclear how GM-CSF-mediated signaling factors are 
related to the induction of MHC class II molecules in any cell type. In this study, we found 
that GM-CSF phosphorylates CREB1 at Ser133 in vitro and that CREB1-CBP protein 
interaction inhibition strongly decreases de novo HLA-DR/ -DP/- DQ expression on 
neutrophil surface. Further, we could demonstrate that GM-CSF-mediated signaling leads 
to the induction of CIITA mRNA transcription, whereas NFY and RFX levels are not 
affected. Conclusively, our data highlight for the first time a major role of GM-CSF-induced 
CREB1 phosphorylation and CIITA induction in APC-like neutrophils.  
Furthermore, it is known that CREB1 is a substrate for various cellular kinases 261  such as 
MSK1 262, pp90RSK (or RSK2) 263, Akt 264, PKA 265 and MAPKAP-2 266. By using pharmacological 
inhibitors specifically targeting these kinases, we demonstrated that MSK1 inhibition 
significantly reduces CREB1 phosphorylation, whereas the other inhibitors targeting pp90RSK, 
Akt and PKA did not affect CREB1 phosphorylation. We therefore strongly support the role of 
MAPK-p38-MSK1-CREB1 signaling axis as driver for de novo MHC class II induction on 
human neutrophils. Another group has shown that LPS or TNF-stimulated human neutrophils 
use the same p38-MSK1-CREB1 axis to produce cytokines 267.  
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Therefore, we postulate that CREB1 is an important transcription factor that regulates a 
vast repertoire of immune responses in neutrophils in inflammation. 
In the present study, we were able to demonstrate that JAK1/2 inhibition at non-toxic 
concentrations leads to full inhibition of GM-CSF-mediated STAT5, mTOR, Akt, p38 and 
CREB1 phosphorylation in human neutrophils, rendering JAK1/2 an interesting drug target 
in neutrophils to cease a huge variety of signaling pathways at once (Abstract online by 
Lopez et al., Blood 2017 130:4805), inclusive those signaling events leading to APC-like 
phenotype. So far, the clinical use of JAK1/2 inhibitors is approved in patients suffering 
from myelofibrosis and rheumatoid arthritis and they are currently in the clinical 
development targeting several indications such as graft-versus-host-disease, pancreatic 
cancer, and myeloproliferative diseases (www.clinicaltrials.gov, recently reviewed by 268). 
It remains to be elucidated whether JAK1/2 inhibitors may be useful as a treatment option 
during the course of sepsis. 
HLA-DR/ -DP/- DQ surface molecule expression on neutrophils co-localizes with CD66b, a 
specific marker consistently expressed on human neutrophil surface independent of the 
cell location, level of activation and disease state 269. Interestingly, nuclear stainings 
revealed that those HLA-DR/ -DP/- DQ+ neutrophils show a segmented nuclei morphology, 
classically known for mature neutrophils 226. This finding is contrary to a report showing 
“APC-like hybrid tumor-associated neutrophils (TANs)” in early stage lung cancer that 
exhibit characteristics of neutrophils and antigen-presenting cells with a round, immature 
cell morphology 157. These discrepancies in relation to nuclear morphology could be 
partially explained by the various factors involved in extravasation and the local tumor 
microenvironment that may influence neutrophil nuclear phenotype. 
Neutrophils are limited in lifespan and difficult to cultivate ex vivo 22,270. We could clearly identify a 
trade-off situation between neutrophil apoptosis and de novo HLA-DR/ -DP/- DQ expression over 
time. Both, GM-CSF and IFN-g have the capacity to reduce neutrophil apoptosis in vitro 20,21. 
Therefore, it is unclear whether de novo HLA-DR/ -DP/- DQ expression is the logical 
consequence of prolonged neutrophil survival in this in vitro system.  For that reason, we used a 
low-dose, effective Pan-Caspase inhibitor q.OPh 225 to reduce neutrophil apoptosis in vitro. The 
Caspase inhibitor q.OPh reduces the extrinsic and intrinsic Caspase-mediated cell death 
pathway, but does not affect de novo HLA-DR/ -DP/- DQ expression on human neutrophils. 
Conclusively, we assume that apoptosis progression and de novo induction of MHC class II are 
two distinguished, intrinsic programs in neutrophils. Moreover, the substantial reduction of 
neutrophil apoptosis by using Pan-Caspase inhibitor q.OPh is an indispensable tool to avoid 
unspecific contamination and binding in experimental procedures such as RNA isolation and T-
cell activation assays in vitro.  
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Classical APCs such as DCs and macrophages orchestrate adaptive immune response by 
T-cell activation. Our data show that APC-like neutrophils are capable to present peptides 
and activate autologous CD4+ T cell clones in vitro. However, T-cell activation by APC-like 
neutrophils is moderate compared to professional APCs such as DCs, in agreement with 
Vono et al 163. By the fact that we were not able to induce CD4+ T-cell proliferation in vitro 
(data not shown), it remains speculative how precisely APC-like neutrophils regulate 
adaptive immune responses in vivo and how they effectively contribute to infection control. 
Further experiments using neutrophil-specific conditional knockout mice defective in MHC 
class II could help to unravel this fundamental question in future experiments.  
In conclusion, this comprehensive analysis of neutrophil immunity in sepsis reveals that 
neutrophils are not only simple foot soldiers that kill pathogens, but also express features 
of atypical APCs when they are exposed to a GM-CSF and IFN-g-rich cytokine 
environment. Despite the ability to induce T-cell responses in vitro by APC-like neutrophils, 
their precise role in infection in vivo needs to be clarified, whether they act as friend or foe. 
Moreover, the MAPK-p38-MSK1-CREB1 axis drives atypical APC-like neutrophil 
phenotype and targeting this particular pathway could have crucial impact in the 
development of new therapies in sepsis. 
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5.2.6 Methods 
Patients and healthy volunteers 
The single-center prospective clinical study was performed at the University Hospital Basel, 
Switzerland. In total, 34 participants with confirmed gram-negative bacteremia (2 or more 
diagnostic criteria for systemic inflammatory response syndrome (SIRS) 271 plus confirmed 
presence of gram-negative bacteria in blood culture, n=24) and healthy controls (n=10) 
matching for age and body mass index were recruited between June and November of 
2016. Exclusion criteria for patients and controls were pregnancy and lipid disorders. One 
patient was excluded due to technical reasons (P6). The study was approved by the ethical 
committee Nordwest- and Zentralschweiz (BASEC Project ID: 2016-00676) and was in 
agreement with the Declaration of Helsinki and Good Clinical Practice (GCP) Guidelines.  
Patient severity was determined according to the recommendations of the Third 
International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) 272. Namely, 
patients with bacteremia/ infection that fulfilled 2 or more criteria of the quick Sequential 
Organ Failure Assessment (qSOFA) score were considered to possibly have sepsis (i.e. 
bacteremia plus organ dysfunction). Patients with bacteremia receiving vasopressor 
therapy required to maintain mean arterial pressure above 65 mmHg and lactate levels >2 
mmol/L despite adequate fluid resuscitation were considered to have septic shock. 
Peripheral blood was drawn within 24h of confirmed bacteremia.  Plasma was obtained by 
centrifugation (10min, 1'600 x g). 
 
Human PMN isolation 
Human PMN were isolated as previously described 46,273. In brief, human peripheral blood 
was collected in 7.5 ml polyethylene tubes containing 1.6 mg EDTA/ml blood (Sarsted), 
mixed with 3% Dextran (Pharmacia) / NaCl solution. The leukocyte-rich plasma was 
transferred to a discontinuous Percoll gradient with 53% and 67% Percoll (GE Healthcare). 
Percoll Gradient centrifugation was performed for 30 min at 1400 rpm, 4°C, no braking. 
The visible ring containing PMN fraction was collected and washed in 0.9% NaCl, 
resuspended in RPMI (Invitrogen Gibco) + 10% fetal bovine serum (FBS) respectively 10% 
human serum. Cells were counted with Türk solution and an automatic cell counter system 
ADAM (Digital Bio). Purity and viability was routinely >97% and >99%, respectively. 
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Pathogen cultures 
Salmonella strains used in this study were derived from Salmonella enterica serovar 
Typhimurium SL1344 hisG rpsL xyl 274,275. Salmonella were cultured at 37°C with aeration 
(200 rpm) in Lennox LB. Salmonella were grown to mid-log phase, washed twice in 
phosphate-buffered saline (PBS) used for in vivo experiments. Heat-inactivation was 
performed at 99°C for 15 min. Heat-inactivated Salmonella were opsonized in 10% human 
serum in PBS for 20 min at 37°C, washed with PBS, and diluted to MOI 200 for immediate 
use (heat-inactivated Salmonella). 
Candida albicans SC5314 was grown overnight in yeast peptone dextrose (YPD, BD Difco) 
media at 37°C as previously described 46. A subculture was inoculated 1:100 and grown to 
mid-log phase. C. albicans was washed twice with 0.9% NaCl and heat-inactivated at 95°C 
for 1h. C. albicans was opsonized in 10% human serum in PBS for 20 min at 37°C, washed 
with PBS and diluted to MOI 1 for immediate use. 
 
Inhibitors and cytokines 
Ruxolitinib (JAK1/2 inhibitor, Cat. No. S1378), PD98059 (MEK1 inhibitor, Cat. No. S1177), 
Trametinib (MEK1/2 inhibitor, Cat. No. S2673), Wortmannin (PI3K inhibitor, Cat. No. 
S2758), Neratinib (EGFR1/2 inhibitor, Cat. No. S2150), LY294002 (PI3K inhibitor, Cat. No. 
S1105), IPA-3 (PAK1 inhibitor, Cat. No. S7093), BX-795 (PDK-1 inhibitor, Cat. No. S1274), 
MK-2206 (Akt1/2/3 inhibitor, Cat. No. S1078), BI-D1870 (RSK1-4 inhibitor, Cat. No. 
S2843), PF-4708671 (S6K1 inhibitor, Cat. No. S2163), SB203580 (p38 MAPK inhibitor, 
Cat. No. S1076), SCH772984 (ERK1/2 inhibitor, Cat. No. S7101), H89 (PKA inhibitor, Cat. 
No. S1582), PP242 (mTORC1/2 inhibitor, Cat. No. S2218), Rapamycin (mTORC1 inhibitor, 
Cat. No. S1039), Atorvastatin (HMG-CoA Reductase inhibitor, Cat. No. S2077), Lovastatin 
(HMG-CoA Reductase inhibitor, Cat. No. S2061) were obtained from Selleckchem, 
SB747651A (MSK1 inhibitor, Cat. No. 4630) was obtained from Tocris, CAS 92-78-4 
(CREB-CBP inhibitor, Cat. No. 217505) was obtained from Calbiochem. Human 
recombinant GM-CSF, IFN-g, IL-6 and IL-18 were ordered by Peprotech. 
 
Sample preparation for Proteomics (LC-MS) analysis 
5x105 freshly isolated human neutrophils were used for proteomics analysis. Cells were 
washed twice with PBS (Sigma) and were lysed in 200 μl lysis buffer (2% sodium 
deoxycholate (SDC), 0.1 M ammoniumbicarbonate) using strong ultra-sonication (two 
cycles of sonication S3 for 10 seconds, Hielscher Ultrasonicator). Protein concentration 
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was determined by BCA assay (Thermo Fisher Scientific) using a small sample aliquot. 
50μg of proteins were digested as described previously 276, reduced with 5 mM TCEP for 
15 min at 95 °C and alkylated with 10 mM iodoacetamide for 30 min in the dark at 25 °C. 
After diluting samples with 100 mM ammonium bicarbonate buffer to a final DOC 
concentration of 1%, proteins were digested by incubation with sequencing-grade modified 
trypsin (1/50, w/w; Promega, Madison, Wisconsin) overnight at 37°C. Then, the samples 
were acidified with 2 M HCl to a final concentration of 50 mM, incubated for 15 min at 37 °C 
and the precipitated detergent removed by centrifugation at 10,000xg for 15 min. 
Subsequently, peptides were desalted on C18 reversed-phase spin columns according to 
the manufacturer’s instructions (Microspin, Harvard Apparatus) and dried under vacuum. 
 
TMT labeling and HpH-fractionation 
The dried peptide samples were subsequently labeled with isobaric tag (TMT 10-plex, 
Thermo Fisher Scientific) according to the manufacturer’s instructions. To control for ratio 
distortion during quantification, a peptide calibration mixture consisting of six digested 
standard proteins mixed in different amounts were added to each sample before TMT 
labeling as recently described 276. After pooling the TMT labeled peptide samples, peptides 
were again desalted on C18 reversed-phase spin columns according to the manufacturer’s 
instructions (Macrospin, Harvard Apparatus) and dried under vacuum. TMT-labeled 
peptides were fractionated by high-pH reversed phase separation using a XBridge Peptide 
BEH C18 column (3,5 µm, 130 Å, 1 mm x 150 mm, Waters) on an Agilent 1260 Infinity 
HPLC system. Peptides were loaded on column in buffer A (ammonium formate (20 mM, 
pH 10) in water) and eluted using a two-step linear gradient starting from 2% to 10% in 5 
minutes and then to 50% (v/v) buffer B (90% acetonitrile / 10% ammonium formate (20 
mM, pH 10) over 55 minutes at a flow rate of 42 µl/min. Elution of peptides was monitored 
with a UV detector (215 nm, 254 nm). A total of 36 fractions were collected, pooled into 12 
fractions using a post-concatenation strategy as previously described 277, dried under 
vacuum and subjected to LC-MS/MS analysis. 
 
Sample preparation for Phosphoproteomic Analysis  
Samples were prepared as previously described 230. In brief, for each condition, 108 
neutrophils were stimulated for 30 minutes without or with GM-CSF. Next, the cells were 
put on ice and washed twice with ice-cold PBS. Samples were collected in urea solution 
(8M Urea (AppliChem, Darmstadt, Germany), 0.1M Ammoniumbicarbonate (Sigma, St. 
Louis, MO), 0.1% RapiGest (Waters, Milford, MA) in the presence of phosphatase inhibitor 
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1x PhosSTOP (Roche, Basel, Switzerland). Supernatants were collected and stored at -
80°C for further processing. BCA Protein Assay (Pierce, Rockford, IL) was used to 
measure protein concentration. 
 
Phosphopeptide Enrichment for Phosphoproteomics  
2mg of total protein lysate was digested with trypsin, cleaned up using an C18 column and 
enriched for phosphorylated peptides using titanium dioxide beads as described 230. After 
C18-cleanup, 1 µg of peptides were LC-MS analyzed as described below with the following 
changes; the normalized collision energy was set to 27%, the mass isolation window was 
set to 1.4 m/z. The acquired raw-files were imported into the Progenesis QI software (v2.0, 
Nonlinear Dynamics Limited), which was used to extract peptide precursor ion intensities 
across all samples applying the default parameters. The generated mgf-files were 
searched using MASCOT as above using the following search criteria: full tryptic specificity 
was required (cleavage after lysine or arginine residues, unless followed by proline); 3 
missed cleavages were allowed; carbamidomethylation (C) was set as fixed modification; 
oxidation (M) and phosphorylation (STY) were applied as variable modifications; mass 
tolerance of 10 ppm (precursor) and 0.02 Da (fragments). The database search results 
were filtered using the ion score to set the false discovery rate (FDR) to 1% on the peptide 
and protein level, respectively, based on the number of reverse protein sequence hits in 
the datasets. The relative quantitative data obtained were normalized and statistically 
analyzed using our in-house script as above 276. 
 
LC-MS/MS Analysis 
The setup of the μRPLC-MS system was as described previously 276. Chromatographic 
separation of peptides was carried out using an EASY nano-LC 1000 system (Thermo 
Fisher Scientific), equipped with a heated RP-HPLC column (75 μm x 37 cm) packed in-
house with 1.9 μm C18 resin (Reprosil-AQ Pur, Dr. Maisch). Aliquots of 1 μg total peptides 
were analyzed per LC-MS/MS run using a linear gradient ranging from 95% solvent A 
(0.15% formic acid, 2% acetonitrile) and 5% solvent B (98% acetonitrile, 2% water, 0.15% 
formic acid) to 30% solvent B over 90 minutes at a flow rate of 200 nl/min. Mass 
spectrometry analysis was performed on Q-Exactive HF mass spectrometer equipped with 
a nanoelectrospray ion source (both Thermo Fisher Scientific). Each MS1 scan was 
followed by high-collision-dissociation (HCD) of the 10 most abundant precursor ions with 
dynamic exclusion for 20 seconds. Total cycle time was approximately 1 s. For MS1, 3e6 
ions were accumulated in the Orbitrap cell over a maximum time of 100 ms and scanned at 
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a resolution of 120,000 FWHM (at 200 m/z). MS2 scans were acquired at a target setting of 
1e5 ions, accumulation time of 100 ms and a resolution of 30,000 FWHM (at 200 m/z). 
Singly charged ions and ions with unassigned charge state were excluded from triggering 
MS2 events. The normalized collision energy was set to 35%, the mass isolation window 
was set to 1.1 m/z and one microscan was acquired for each spectrum. 
 
Protein Quantification and Database Searching 
The acquired raw-files were converted to the mascot generic file (mgf) format using the 
msconvert tool (part of ProteoWizard, version 3.0.4624 (2013-6-3)). Using the MASCOT 
algorithm (Matrix Science, Version 2.4.1), the mgf files were searched against a decoy 
database containing normal and reverse sequences of the predicted SwissProt entries of 
Homo sapiens (www.ebi.ac.uk, release date 2014/11/24), the six calibration mix proteins 276 
and commonly observed contaminants (in total 84,610 sequences for Homo sapiens) 
generated using the SequenceReverser tool from the MaxQuant software (Version 
1.0.13.13). The precursor ion tolerance was set to 10 ppm and fragment ion tolerance was 
set to 0.02 Da. The search criteria were set as follows: full tryptic specificity was required 
(cleavage after lysine or arginine residues unless followed by proline), 3 missed cleavages 
were allowed, carbamidomethylation (C), TMT6plex (K and peptide n-terminus) were set as 
fixed modification and oxidation (M) as a variable modification. Next, the database search 
results were imported to the Scaffold Q+ software (version 4.3.2, Proteome Software Inc., 
Portland, OR) and the protein false identification rate was set to 1% based on the number 
of decoy hits. Protein probabilities were assigned by the Protein Prophet program 278. 
Proteins that contained similar peptides and could not be differentiated based on MS/MS 
analysis alone were grouped to satisfy the principles of parsimony. Proteins sharing 
significant peptide evidence were grouped into clusters. Acquired reporter ion intensities in 
the experiments were employed for automated quantification and statically analysis using a 
modified version of our in-house developed SafeQuant R script, v2.3 276. This analysis 
included adjustment of reporter ion intensities, global data normalization by equalizing the 
total reporter ion intensity across all channels, summation of reporter ion intensities per 
protein and channel, calculation of protein abundance ratios and testing for differential 
abundance using empirical Bayes moderated t-statistics. Finally, the calculated p-values 
were corrected for multiple testing using the Benjamini−Hochberg method.  
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Mouse Infections and Tissue Collection 
All animal experiments were approved (license 2890, Kantonales Veterinäramt Basel) and 
performed according to local guidelines (Tierschutz-Verordnung, Basel) and the Swiss 
animal protection law (Tierschutz-Gesetz). C57BL/6J congenic mice were infected by tail 
vein injection of 1000 +/- 200 Salmonella in 100 µl PBS and euthanized days 1, 2, 3 or 4 
post infection. Spleen, liver, blood and bone marrow was collected from each mouse and 
dissected into several pieces if needed. CFU counts were determined by plating.  
 
Sample preparation for Salmonella-infected host proteomics  
Spleen cells were carefully extracted mechanically by pressing spleens with two glass 
slides. The resulting cells were passed through 40-micron cell strainer (BD Falcon). Cell 
were then spun down and resuspended in cold red blood cell lysis buffer (Sigma) and 
incubated at room temperature for 5 minutes with gentle shaking. Cells were passed again 
through a cell strainer, washed once with PBS, and resuspended in FACS buffer (PBS, 
0.5% BSA, 2mM EDTA) containing the following antibodies: CD11b-PE (clone M1/70, BD 
Biosciences), Ly6C-FITC (clone AL-21, BD Biosciences), Ly6G-APCCy7 (clone 1A8, 
Biolegend). Cells were incubated on ice for 30 minutes. Neutrophils (CD11b+, Ly6CInt, 
Ly6G+) were sorted with a FACSAria (BD Biosciences) into Falcon tubes containing RPMI 
+ 2% FCS. Neutrophils were washed once with cold PBS and pellets were kept at -80°C 
until further processing. 
 
Comparison of human and mouse proteome 
Human and mouse differential protein expression was compared using human-mouse 
homology information from the ENSEMBL database (release 90; 
http://aug2017.archive.ensembl.org/) 249. The one-to-one orthologs between the two 
species were retrieved, along with their corresponding Entrez IDs, with the R package 
biomaRt (version 2.32) 279 from Bioconductor release 3.5 280. Only orthology relations 
annotated at the taxonomic level Euarchontoglires or Eutheria were retained. The merged 
human and mouse proteomics data set included in total 1157 orthologous proteins. The 
Venn diagram displaying shared differentially expressed proteins was drawn using the 
Bioconductor package limma (version 3.32) 281. Significance level of both proteomic data 
were set at FDR > 0.05. 
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ROS production assay of human neutrophils 
ROS production was measured using luminol-enhanced chemoluminescence, as 
previously described 46. In brief, 2x105 cells were incubated in RPMI+ 10% human serum 
for 1h at 37°C, 5% CO2 without inhibitors, or with 10 μM DPI. Neutrophils were stimulated 
with opsonized Salmonella (MOI=100 and 200) or Candida albicans (MOI=2) in the 
presence of 10% human serum and 100 μM luminol (Fluka) in HBSS (Invitrogen, Gibco) 
containing 0.1% glucose (Braun). Chemiluminescence was measured at 5 min intervals at 
37°C with a luminometer (Microlumat Plus, Berthold Technologies). Values were corrected 
based on unstimulated controls and initial time points.  
 
Phosflow Assay with flow cytometry  
p-Akt (pS473, BD PhosflowTM, Cat. No 558434), p-mTOR (pS2448, BD PhosflowTM, Cat. 
No 564242), p-p38 (pT180/pY182, BD PhosflowTM, Cat. No 612595), p-STAT5 (pY694, BD 
PhosflowTM, Cat. No 612598), and p-CREB (pS133, BD PhosflowTM, Cat. No 558434) in 
human neutrophils were measured by flow cytometry using an adapted BD PhosflowTM 
protocol for human PBMCs. In brief, 500’000 PMN were pre-treated with inhibitors for 1h, 
washed twice, then stimulated with GM-CSF or PMA (Sigma, 10nM, as positive control) for 
30min. The cells were fixed with 1x BD PhosflowTM Fix buffer I (BD, Cat. No. 557870) for 12 
min at 37°C, then permeabilized using BD PhosflowTM Perm buffer III (Cat. No. 558050) on 
ice for 30 min, followed by indicated PhosflowTM antibody staining for another 1h at room 
temperature. Unspecific Fc receptor blocking (Human TruStain FcXTM, Biolegend, Cat. No. 
422301) and surface staining with FITC anti-human CD66b (Clone: G10F5, Biolegend) or 
APC anti-human CD66b (Clone: G10F5, Biolegend) for 1h was performed immediately 
before fixation for 30min. The stainings were initially performed with respective IgG isotype 
control (BD, Cat. No. 5577839. For data analysis, CD66+ cells were initially gated to check 
SSC/ FSC position in FACS plot. Data were obtained using FACS CytoFlex (Beckman 
Coulter) and analyzed by using FlowJo v10.4.1.  
 
Surface Molecule staining for flow cytometry 
After PMN isolation or stimulation with cytokines, human neutrophils were washed twice in 
PBS to remove all cell debris and cytokines. To reduce unspecific antibody binding, 
neutrophils were incubated for 15min at room temperature in presence of human TruStain 
FcXTM Blocking solution (Biolegend, Catalog No.: 422302, 2µl/test) or mouse TruStain 
fcXTM (anti-mouse CD16/Cd32) blocking antibodies (Biolegend, Catalog No.:  
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101320, 2µl/test) followed by antibody staining for 30 minutes in the dark at 4°C. Samples 
were acquired with a BD Fortessa or Cytoflex (Beckman Coulter) flow cytometer. Data 
were analysed using FlowJo software, version v10.4.1. As a negative control, unstimulated 
sample or isotype control was used. Antibodies for PE anti-human HLA-DR/ -DP/ -DQ 
(Clone: REA332, Miltenyi), PE-Cy7 anti-human HLA-DR (Clone: Tü39, Biolegend), APC 
anti-human HLA-DR (Clone: L243, Biolegend), APC-Cy7 anti-human HLA-DR (Clone: 
L243, Biolegend), FITC anti-human CD66b (Clone: G10F5, Biolegend), APC anti-human 
CD66b (Clone: G10F5, Biolegend), APC anti-human CD74 (Clone: LN2, Biolegend), APC-
Cy7 anti-human HLA-A, -B, -C (W6/32, Biolegend), FITC mouse isotype control IgM 
(Clone: MM-30, Biolegend), APC-Cy7 mouse isotype control IgG1 (Clone: MOPC-21, 
Biolegend), PE-Cy7 mouse isotype control IgG2a (Clone: MOPC-21, Biolegend), APC 
mouse isotype control IgG1 (Clone: MOPC-21, Biolegend),  APC mouse isotype control 
IgG2a (Clone: MOPC-21, Biolegend), APC-Cy7 mouse isotype control IgG2a (Clone: 
MOPC-173, Biolegend), APC mouse isotype control IgG2a (Clone: MOPC-173, Biolegend) 
were used. Zombie UV Fixable Viability Kit (Biolegend), Alexa647 anti-mouse CD45 
(Clone: 30-F11, Biolegend), PerCP/Cy5.5 anti-mouse CD11b (Clone: M1/70, Biolegend), 
APC/Cy7 anti-mouse CD11c (Clone: N418, Biolegend), BV650 anti-mouse Ly6G (Clone: 
1A8, Biolegend), PE/Cy7 anti-mouse Ly6C (Clone: HK1.4, Biolegend), BV711 anti-mouse 
I-A/I-E (Clone: M5/114.152, Biolegend) were used. 
 
CD4+ T-cell clone activation in vitro 
Antigen-specific CD4+ T-cell clones for the A. fumigatus 15-mer antigen Crf1/p41 were 
generated and expanded using the rapid expansion protocol as previously described 282,283. 
Mature dendritic cells were generated from autologous PBMC as previously published 257,284. 
Autologous PMN were stimulated with GM-CSF (10 ng/ml) and IFN-γ (1 ng/ml) in the 
presence of Pan-Caspase q.OPh (3 µM) for 48h. T-cell stimulation was analyzed by 
intracellular cytokine staining as previously published 227,284. Briefly, DCs and PMNs were 
pulsed with 1 µg/ml Crf1/p41 peptide at 37°C for 30min, then washed twice to remove 
unspecific antigen. DCs and PMNs were co-incubated with the CD4+ T-cell clones (1x105 
cells) in a ratio of 1:1 respectively 10:1 in RPMI with 5% human serum supplemented with 
q.OPh Pan-Caspase inhibitor (3 µM) at 37°C for 6h in the presence of Brefeldin A (10 
µg/ml) for the last 5h. Cells were stained with Zombie Aqua Fixable Viability Dye 
(Biolegend, Cat. No. 423101), CD3-BrilliantViolet785 (Biolegend, Cat. No. 317330), CD4-
BrilliantViolet650 (Biolegend, Cat. No. 317436), IFN-γ-APC (Biolegend Cat. No. 502512) 
and TNF-α-PE/Cy7 (Biolegend, Cat. No. 502930). 
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Caspase activity assay 
FAM-FLICA Caspase-3/-7 Assay Kit (Cat. No. 93), FAM-FLICA Caspase-8 Assay Kit (Cat. 
No. 99), FAM-FLICA Caspase-9 Assay Kit (Cat. No. 912), and FAM-FLICA Poly Caspase 
Assay Kit (Cat. No. 91) were ordered from ImmunoChemistry Technologies. Reagents 
were dissolved in DMSO as indicated by manufacturer’s instruction. 1x FLICA Caspase 
solution was added to 300’000 neutrophils/ condition in a volume of 100µl for 30min at 
37°C, then washed twice with FACS buffer and analyzed for its fluorescence in FL-1 
channel with a flow cytometer (Accuri C6, BD). 
 
Caspase inhibition assay 
Caspase inhibitors for Caspase-3, Caspase-6, Caspase-7, Caspase-8 and Caspase-9 
were ordered from R&D (Sampler Pack, Cat. No. FMKSP01) and Pan-Caspase OPH 
inhibitor Q-VD (short q.OPh, R&D systems, Cat. No. OPH001). In brief, 100’000 
neutrophils/ condition were pre-treated with Caspase inhibitors (final concentration = 
[10µM] for sampler pack inhibitors, final concentration = [3µM] for Pan-Caspase OPH 
inhibitor Q-VD) for 18h, then washed with FACS buffer and stained for propidium iodide 
(PI; 1:100) and Annexin V-APC (1:100) for 15 min at room temperature. Sample acquisition 
was done in between 2 hours by using FL-2 (PI) and FL-4 (APC) on Accuri C6 flow 
cytometer (BD). 
 
Annexin V assay 
Followed by antibody staining, the cells were washed and re-buffered in FACS buffer 
supplemented with 2.5mM CaCl2, stained with Annexin V (1:100) for 15 min at room 
temperature and washed in FACS buffer. Sample acquisition was done in between 2 hours. 
BV421 Annexin V (Biolegend), APC Annexin V (Biolegend) and FITC Annexin V 
(Biolegend) were used. 
 
Cytokine measurements in human plasma 
Peripheral blood was drawn in 2.7ml polyethylene tubes (Sarsted), spun down at 1’600 x g for 10 
min and plasma-rich supernatant (upper phase) was collected and stored at –80°C until further 
processing. Cytokines in plasma were measured using the customized human LEGENDplexTM 
multi-analyte flow assay kit (Biolegend) for IL-13, IL-2, GM-CSF, IL-9, IL-10, IFN-g, TNF-a, IL-
17A, IL-6, IL-4, IL-21, IL-2 and IL-17F, according to manufacturer’s instructions. 
 
 
72 
 
ImageStreamX 
2x106 cells were plated in a 96-well plate, followed by human TruStain FcXTM blocking for 
15min at 4°C (Biolegend, Catalog No.: 422302) and antibody staining (HLA-DR/DP/DQ-PE, 
Miltenyi Biotec, No. 130-104-827 and CD66b-AlexaFluor647, Biolegend, No. 305110) for 
30min in the dark at 4°C. Cells were fixed with Fixation buffer (Biolegend, No. 420801) for 
20min at room temperature, permeabilized with Permeabilization Wash buffer (Biolegend, 
No. 421002) and stained with DAPI (final conc. 0.5µg/ml) for 5min at room temperature. 
Cells were resuspended in FACS buffer and acquired with ImageStream X Mark II Imaging 
Flow cytometer (EMD Millipore) at 60x magnification using the channels CH1 (brightfield), 
CH3 (HLA-DR/DP/DQ-PE), CH7 (DAPI) and CH11 (CD66b-AlexaFluor647). 
 
mRNA determination and RT-PCR 
Total RNA was extracted from 10x106 human neutrophils at 4h, 24h and 48 of incubation by 
using the RNAeasy mini kit (Qiagen, Cat. No. 74104) according to manufacturer’s instructions, 
with a second RNA purification step to optimize RNA yield and purity 285. RNA concentration was 
measured with NanoDrop (Thermo Fisher Scientific), and purity was determined with the ratio 
260nm/280nm method. cDNA synthesis was performed with the Omniscript RT kit (Qiagen, Cat. 
No. 2051119). mRNA expression was measured by real-time PCR using the FastStart Universal 
SYBR Green Master (Roche, Cat. No. 04 913 850 001). The deltadelta Ct method 286 was used 
to obtain the relative mRNA expression using GAPDH and B2M as internal controls (HK) 287. 
Samples were run in technical triplicates. Results are shown as fold change relative to 
unstimulated and internal control. The following primers were used: CIITA (forward: CTG AAG 
GAT GTG GAA GAC CTG GGA AAG C, reverse: GTC CCC GAT CTT GTT CTC ACT C), B2M 
(forward: ACT GAA TTC ACC CCC ACT GA, reverse: CCT CCA TGA TGC TGC TTA CA), 
HLA-DRA (forward: GAG TTT GAT GCT CCA AGC CCT CTC CCA, reverse: CAG AGG CCC 
CCT GCG TTC TGC TGC ATT), CD74 (forward: CAC CTG CTC CAG AAT GCT G, reverse: 
CAG TTC CAG TGA CTC TTT CG), RFX5 (forward: GTG TTT ATG ATG CCT ATC GGA AGT, 
reverse: TCC TCC TTA TGC CAC TGT AGC), CREB (forward: ATG GAA TCT GGA GCC GAG 
AA, reverse: GTG GCT GGG CTT GAA CTG), RFXANK (forward: TGA GAC CGT TCG CTT 
CCT, reverse: GTC CCT CCA TTC CAA TCA TAG ATG), NFYa (forward: GCC AGG CAA TGT 
GGT CAA, reverse: GCT TCT TCA TCG GCT TGG TT), GAPDH (forward: AAG TAT GAC AAC 
AGC CTC AAG AT, reverse: CAT GAG TCC TTC CAC GAT ACC), NLRC5 (forward: GAG AGT 
GGA CCT GGA GAA GA, reverse: GCG GAT GAC TTG GAT GCT A), HLA-B (forward: TGA 
GAT GGG AGC CGT CTT, reverse: CAC GCA GCC TGA GAG TAG). 
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Statistical analysis 
Comparisons between unpaired groups with a nonparametric distribution were made using 
the Mann-Whitney test. Comparisons between paired groups with a nonparametric 
distribution were made using Wilcoxon matched-pairs signed rank test. P values < 0.05 
were considered statistically significant. Statistical analysis was performed with GraphPad 
Prism 7 software. 
 
Data availability 
The data that support the findings of this study are available from the corresponding author 
upon request. Proteomics data will be uploaded upon paper submission. 
Correspondence and requests for materials should be addressed to N.K. 
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Fig. 1: Human neutrophils in sepsis show APC-like phenotype.  
a, Human peripheral blood-derived neutrophil counts (PMN, in x106 cells) of control (n=10) and 
sepsis patients (n=23), counted with ADAM automated cell counter system. All values are shown as 
medians (Mann-Whitney test; **, P< 0.01).  
b, Number of peptides (n=2204) identified by human neutrophil proteomics from control (n=9) and 
sepsis patients (n=10) with significant increased (n=317) and decreased (n=63) peptide levels. 
Significance threshold was set at P-value < 0.02.  
c, Enriched pathways from proteomics analysis on human neutrophils from control (n=9) and sepsis 
patients (n=10), using Metacore Enrichment by Pathway Maps. P-value of proteomics data was set 
< 0.05, threshold = 0, listed are the top 20 hits with an enrichment significance of P-value < 0.01. 
Identified protein counts are indicated in brackets. Red bars highlight Antigen Presentation and 
processing by MHC class I and MHC class II as highly changed pathways in sepsis.   
d, Volcano dot plot from proteomics analysis on human neutrophils from control (n=9) and sepsis 
patients (n=10). Highlighted proteins (red dots) are associated with Antigen presentation and 
processing by MHC class I and II, significance threshold (dotted line) was set at P-value < 0.02 and 
fold change £ 1.5 cut-off in order of P-value.  
e, Heat map of proteins involved in Antigen presentation and processing by MHC class I and II in 
human neutrophils from control (n=9) and sepsis patients (n=10), shown on an individual level with 
log2 ratio, normalized (0-1, blue to yellow). Significance threshold was set at P-value < 0.02 and fold 
change £ 1.5 cut-off in order of P-value. Protein names are used according to entry names in 
UniProt database (www.uniprot.org).  
f, Representative histogram of HLA-A, -B, -C surface expression (Mean Fluorescence Intensity) on 
human neutrophils of control (white) and sepsis patient (grey), measured with flow cytometry and 
summarized for control (n=10) and sepsis patients (n=10). All values are shown as medians (Mann-
Whitney test; **, P < 0.01).  
g, Representative scatter dot plot of CD66b and HLA-DR/ -DP/ -DQ surface expression on human 
neutrophils of control (left panel) and sepsis patient (right panel), measured with flow cytometry and 
summarized for control (n=9) and sepsis patients (n=9). Red numbers are highlighting percentage of 
population. All values are shown as medians (Mann-Whitney test; ***, P < 0.001).  
h, Plasma cytokine concentration for IL-6, GM-CSF, IFN-g, MCP-1 and IL-18 of control (n=10) and 
sepsis patients (n=17). Concentrations are indicated in [pg/ml] and interpolated to a non-linear 
standard curve fit. All values are shown as medians (Mann-Whitney test; *, P< 0.05; ****, P< 
0.0001).  
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Fig. 2: IFN-g and GM-CSF induce APC-like neutrophil phenotype in vitro.  
a, Representative scatter dot plot of HLA-DR/ -DP/ -DQ and Annexin V surface expression on 
human neutrophils (CD66b+ cells) after stimulation with human recombinant GM-CSF (10 ng/ml), 
IFN-g (10 ng/ml), IL-6 (10 ng/ml) and IL-18 (10 ng/ml) for 48h, pre-incubated -/ + Pan-Caspase 
inhibitor q.OPh (3µM) for 1h, measured with flow cytometry. Red squares are highlighting the 
percentage of HLA-DR/ -DP/ -DQ+ /Annexin V- population.  
b, Percentage of HLA-DR/ -DP/ -DQ+ /Annexin V- neutrophils after pre-incubation with -/ + Pan-
Caspase inhibitor q.OPh (3µM) and stimulation with human recombinant GM-CSF (10 ng/ml), IFN-g 
(10 ng/ml), IL-6 (10 ng/ml) and IL-18 (10 ng/ml) for 48h. All values are shown as medians (n=6; 
Mann-Whitney test; *, P< 0.05).  
c, Percentage of HLA-DR/ -DP/ -DQ+ /Annexin V- neutrophils after pre-incubation with -/ + Pan-
Caspase inhibitor q.OPh (3µM) and stimulation with human recombinant GM-CSF (10 ng/ml) and 
IFN-g (10 ng/ml) for 48h. All values are shown as medians (n=18; Mann-Whitney test; ****, P< 
0.0001).  
d, Representative example of de novo MHC class II (HLA-DR/ -DP/ -DQ) surface molecule 
expression on neutrophils after stimulation with human recombinant GM-CSF (10 ng/ml) and IFN-g 
(10 ng/ml) for 48h, measured with Image Stream X (left) and summarized (right, n= 3). DAPI was 
used for nuclear staining and CD66b as surface expression marker. BF, Bright field.  
e, HLA-DR and Li (CD74) mRNA expression after stimulation with human recombinant GM-CSF (10 
ng/ml) and IFN-g (10 ng/ml) for 4, 24 and 48h. Values are shown as relative fold change to 
unstimulated control and internal control (housekeeping genes, HK). All values are shown as 
medians (n=6; Mann-Whitney test; *, P< 0.05; ns, not significant).  
f, Representative overlay of de novo MHC class II (HLA-DR/ -DP/ -DQ, orange) surface molecule 
expression on neutrophils after stimulation with human recombinant GM-CSF (10 ng/ml) and IFN-g 
(10 ng/ml) for 48h, measured by Image Stream X at 60x magnification. DAPI (blue) was used for 
nuclear staining and CD66b as surface expression marker.  
g, Intracellular cytokine staining for IFN-g and TNF-a-activated viable CD3+ CD4+ T cells, co-
incubated with and without antigen-pulsed PMN (control, ratio 1:10) and cytokine-stimulated PMN 
(recombinant GM-CSF, 10 ng/ml; recombinant IFN-g, 1 ng/ml, ratio 1:10) for 6 hours. 
Representative scatter dot plot (left) and summarized in percentage for IFN-g (middle) and TNF-a 
(right).  As a positive control, autologous dendritic cells (DCs, 1:1 ratio) and T-cell clones alone were 
used. All values are shown as medians with interquartile ranges (n=11; n=6 for positive control with 
DCs; Wilcoxon signed rank test; **, P< 0.01).	  
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Fig. 3: GM-CSF signaling leads to the activation of JAK-STAT, MAPK p38 and Akt-mTOR 
signaling pathways and phosphorylation of transcription factor CREB1. 
a, Visualization of phosphoproteomics experimental procedure. Neutrophils (108 cells each 
condition) were unstimulated or stimulated with GM-CSF (10 ng/ml) for 30min and then collected for 
further processing.  
b, Volcano dot plot of detected phosphopeptide changes (n=3579) after stimulation with GM-CSF 
for 30min. Significance threshold was set at q-value < 0.05 and fold change £ 2 cut-off in order of P-
value. Phosphopeptides belonging to PI3K-Akt-mTOR signaling were shown in red, 
phosphopeptides belonging to JAK-STAT signaling were shown in blue, and phosphopeptides 
belonging to MAPK signaling were shown in orange. Phosphopeptides directly linked to Antigen 
presentation and processing were indicated in black.  
c, Overrepresented phosphorylation motifs after stimulation with GM-CSF for 30min. The 
overrepresented phosphorylation motifs were extracted with MOTIF-X software tool, V1.2. Ten 
distinct motifs were identified with significance < 0.000035 (p-value < 0.01), peptide width of 15 and 
occurrence of 5 (left). Putative kinases responsible for the phosphorylation of the ten observed, 
significant motifs are indicated (right, in red). Putative kinases were predicted using PhosphoELM, 
SwissProt (RegPhos 1.0, www.regphos-mbc.nctu.edu.tw) and extensive literature research.  
d, Representative histograms for STAT5- (Y694), mTOR- (S2448), Akt- (S473), and p38- 
(T180/Y182) phosphorylation after GM-CSF stimulation for 30min by using PhosFlow antibodies for 
flow cytometry. Unstimulated control is shown in white, GM-CSF stimulation is shown shaded.  
e, Quantification of flow cytometry data as shown in d, with absolute values in MFI (mean 
fluorescence intensity) or relative values in fold changes to control. Inhibitors Ruxolitinib (DJAK1/2 
inhibitor, final conc. = 3µM), BX-795 (DPDK1 inhibitor, final conc. = 10µM), MK-2206 (DAkt1/2/3 
inhibitor, final conc. = 10µM), and PP242 (DmTORC1/2 inhibitor, final conc. = 5µM) were used (n = 
4-17; Wilcoxon signed rank test, ****, P< 0.0001; **, P< 0.01; *, P< 0.05).  
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Fig. 4: Targeting the MHC class II enhanceosome in human neutrophils.  
a, Representative histogram for CREB1 phosphorylation (S133) after GM-CSF stimulation (grey) 
compared to unstimulated (white) for 30min by using PhosFlow antibody for flow cytometry. 
Quantification of flow cytometry data are shown with relative fold changes to control. Inhibitors 
Ruxolitinib (DJAK1/2 inhibitor, final conc. = 3µM), SB 747651 A (DMSK1 inhibitor, final conc. = 
10µM), BI-D1870 (DRSK1-4 inhibitor, final conc. = 10µM), and MK-2206 (DAkt1/2/3 inhibitor, final 
conc. = 10µM), CAS 92-78-4 (DCREB-CBP interaction inhibitor, final conc. = 50µM) were used (n = 
2-12; Wilcoxon signed rank test, ****, P< 0.0001; **, P< 0.01; *, P< 0.05).  
b, CIITA mRNA expression after stimulation with human recombinant GM-CSF (10 ng/ml) for 4, 24 
and 48h. Values are shown as relative fold change to unstimulated control and internal control 
(housekeeping genes, HK). All values are shown as medians (n=6; Wilcoxon signed rank test; *, P< 
0.05).  
c, NFYa, CREB and RFXank mRNA expression after stimulation with human recombinant GM-CSF 
(10 ng/ml) for 4h. Values are shown as relative fold change to unstimulated control and internal 
control (housekeeping genes, HK). All values are shown as medians (n=6; Wilcoxon signed rank 
test; ns, not significant).  
d, Representative scatter dot plot of HLA-DR/ -DP/ -DQ and Annexin V surface expression on 
human neutrophils (CD66b+ cells) after stimulation with human recombinant GM-CSF (10 ng/ml) for 
48h, pre-treatment with CAS 92-78-4 (DCREB-CBP interaction inhibitor, final conc. = 50µM). Red 
labels are indicating the percentage of population. Pan-Caspase inhibitor q.OPh (3µM) was used for 
all conditions. Percentage of HLA-DR/ -DP/ -DQ+ /Annexin V- neutrophils after pre-incubation with/ 
without CAS 92-78-4 inhibitor (DCREB-CBP interaction inhibitor, final conc. = 25, 50 and 100µM) 
and stimulation with human recombinant GM-CSF (10 ng/ml) for 48h. All values are shown as 
medians (n=10-12; Wilcoxon signed rank test; ***, P< 0.001; **, P< 0.01).  
e, Percentage of HLA-DR/ -DP/ -DQ+ /Annexin V- neutrophils after pre-incubation with/ without 
inhibitors Ruxolitinib (DJAK1/2 inhibitor, final conc. = 3µM), SB203580 (Dp38 inhibitor, final conc. = 
10µM), SB 747651 A (DMSK1 inhibitor, final conc. = 10µM), Trametinib (DMEK1/2 inhibitor, final 
conc. = 10µM), and SCH772984 (DERK1/2 inhibitor, final conc. = 5µM), and stimulation with human 
recombinant GM-CSF (10 ng/ml) for 48h. All values are shown as medians (n=2-20; Wilcoxon 
signed rank test; ***, P< 0.001; **, P< 0.01).  
f, Human neutrophil signaling cascade leading to de novo MHC class II induction after stimulation 
with GM-CSF. JAK1/2, Janus Kinase 1 and 2; STAT5, Signal Transducer and Activator of 
Transcription 5; Y694, Tyrosine phosphorylation site at residue 694; CIITA, MHC class II 
transactivator; p38, p38 mitogen-activated protein kinase; MSK1, Mitogen- and stress-activated 
protein kinase-1; RFX, Regulatory factor X; CREB1, cAMP responsive element binding protein 1; 
Pol II; Polymerase II; CBP, CREB-binding protein; HLA-DR, HLA-DM, Li, MHC class II genes. 
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Fig. 5: Induction of APC-like neutrophils in a systemic Salmonella mouse model mimicking 
human typhoid fever. 
a, Overview of experimental Salmonella enterica serovar Typhimurium SL1344 infection procedure 
in wildtype C57BL/6 mice. Bone marrow, blood, spleen and liver were collected at day 1, day 2, day 
3 and day 4.  
b, Representative scatter density plot of splenic Ly6C and Ly6G from viable CD45+ CD11b+ 
population, uninfected or infected with Salmonella enterica serovar Typhimurium SL1344 at day 3. I-
A/ I-E expression on Ly6G+/ Ly6Cdim cells is indicated in percentage (green). LD, live/dead marker.  
c, I-A/ I-E+ cells (in percent) from Ly6G+/ Ly6Cdim population in bone marrow, blood, spleen and liver 
over day 1, day 2, day 3 and day 4 of Salmonella enterica serovar Typhimurium SL1344 infection 
are shown. All values are shown as means (n=4-8; Mann-Whitney test; ***, P< 0.001; **, P< 0.01).  
d, CFU per total organ from bone marrow, blood, spleen and liver over day 1, day 2, day 3 and day 
4 of Salmonella enterica serovar Typhimurium SL1344 infection are shownon a logarithmic scale. 
All values are shown as means (n=4-8; Mann-Whitney test; **, P< 0.01).  
e, Heat map of proteins involved in Antigen presentation and processing by MHC class I and II in 
splenic, murine neutrophils from control (uninfected, 1-3) and infected with Salmonella enterica 
serovar Typhimurium SL1344 (4-6), shown on an individual level with log2 ratio, normalized (0-1, 
blue to yellow). Significance threshold was set at P-value < 0.03 and fold change £ 1.5 cut-off in 
order of P-value. Protein names are used according to entry names in UniProt database 
(www.uniprot.org).  
f, The Venn diagram is showing the comparison of the proteome data sets from isolated splenic 
murine neutrophils infected with Salmonella enterica serovar Typhimurium at day 4 and the human 
peripheral blood derived neutrophils in sepsis in terms of common differential protein expression by 
using one-to-one orthologous homology information. In total identified orthologous proteins 
(n=1157) in humans and mice were indicated below. Differentially expressed, orthologous proteins 
in humans and mice are indicated in red (n=52, FDR<0.05).  
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Table 1: Clinical characteristics of patients and controls    
 Patients 
 
(n=23) 
Controls 
 
 (n=10) 
Demographic characteristics   
Age, years (median, IQR) 74 (69-85) 76 (69-83) 
Male (n, %) 13 (57) 6 (60) 
BMI (median, IQR) 25.3 (20.8-27.5) 25.5 (23.5-32.0) 
Infection type   
Urinary tract (n, %) 17 (74) - 
Pulmonary (n, %) 2 (8.7) - 
Intestinal (n, %) 4 (17.3) - 
Bacterial species   
Escherichia coli (n, %) 17 (74) - 
Pseudomonas aeruginosa (n, %) 2 (8.7) - 
Klebsiella oxytoca (n, %) 1 (4.3) - 
Klebsiella pneumonia (n, %) 1 (4.3) - 
Serratia marcescens (n, %) 1 (4.3) - 
Proteus mirabilis (n, %) 1 (4.3) - 
Severity*    
Infection 21 (91.3) - 
Sepsis 2 (8.7) - 
Septic shock 0 (0) - 
Neutrophil-to-Lymphocyte ratio (median, interquartile 
range) 
6.7 (5.1-17.2) 1.9 (1.3-3.0) 
C-reactive protein** (median, IQR) 
 
Pro-Calcitonin*** (median, IQR) 
144.8 (118.4-271.8) 
 
0.6 (0.28-37.0) 
- 
 
- 
Outcome (d30 mortality) (n, %) 1 (4.3) 0 (0) 
   
* Sepsis-3 definition with qSOFA score after (Singer et al., JAMA 2016) 
** CRP is measured in mg/L. Normal values are below 10mg/L. 
*** Pro-Calcitonin is measured in ng/ml. Normal values are below 0.5 ng/ml. 
 
IQR= interquartile range 
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Uniprot ID Protein Fold Change (log2) q-value
P14625 Endoplasmin (ENPL_HUMAN) 0.6 0.005
P07900 Heat Shock Protein HSP 90-alpha (HS90A_HUMAN) 0.61 0.008
P30480 HLA class I histocompatibility antigen, B-42 alpha chain (1B42_HUMAN) 0.61 0.013
Q31612 HLA class I histocompatibility antigen, B-73 alpha chain (1B73_HUMAN) 1.49 0.020
P30483 HLA class I histocompatibility antigen, B-45 alpha chain (1B45_HUMAN) 2.14 0.038
P27797 Calreticulin (CALR_HUMAN) 0.63 0.025
Q03518 Antigen peptide transporter 1 (TAP1_HUMAN) 1.52 0.007
Q15436 Protein Transport Protein Sec23A (SC23A_HUMAN) 0.66 0.017
P49721 Proteasome subunit Beta type 2 (PSB2_HUMAN) 0.65 0.026
Q9NZ08 Endoplasmatic reticulum aminopeptidase 1 (ERAP1_HUMAN) 1.10 0.037
O15533 Tapasin (TPSN_HUMAN) 0.88 0.017
Q92598 Heat shock protein 105 kDa (HS105_HUMAN) 2.19 0.002
F
Antigen presentation by MHC class I
Antigen presentation by MHC class I: Cross-presentation
Uniprot ID Protein Fold Change (log2) q-value
P14625 Endoplasmin (ENPL_HUMAN) 0.6 0.005
P07900 Heat Shock Protein HSP 90-alpha (HS90A_HUMAN) 0.61 0.008
O15533 Tapasin (TPSN_HUMAN) 0.88 0.017
P51159 Ras-related protein Rab-27A (RB27A_HUMAN) 0.63 0.002
Q9Y4L1 Hypoxia up-regulated protein 1 (HYOU1_HUMAN) 1.11 0.003
P12314 High affinity immunoglobulin gamma Fc receptor I (FCGR1_HUMAN) 1.67 0.028
Q92598 Heat shock protein 105 kDa (HS105_HUMAN) 2.19 0.002
Uniprot ID Protein Fold Change (log2) q-value
P14625 Endoplasmin (ENPL_HUMAN) 0.6 0.005
P07900 Heat Shock Protein HSP 90-alpha (HS90A_HUMAN) 0.61 0.008
P05771 Protein Kinase C beta type (KPCB_HUMAN) 0.74 0.039
P61163 Alpha-centractin (ACTZ_HUMAN) 0.6 0.029
Antigen presentation by MHC class II
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Uniprot ID Protein
Fold Change 
(log2) q-value
P14625 Endoplasmin (ENPL_HUMAN) 0.6 0.005
P07900 Heat Shock Protein HSP 90-alpha (HS90A_HUMAN) 0.61 0.008
Q92598 Heat shock protein 105 kDa (HS105_HUMAN) 2.19 0.002
P30480 HLA class I histocompatibility antigen, B-42 alpha chain (1B42_HUMAN) 0.61 0.013
Q31612 HLA class I histocompatibility antigen, B-73 alpha chain (1B73_HUMAN) 1.49 0.020
P30483 HLA class I histocompatibility antigen, B-45 alpha chain (1B45_HUMAN) 2.14 0.038
P27797 Calreticulin (CALR_HUMAN) 0.63 0.025
Q03518 Antigen peptide transporter 1 (TAP1_HUMAN) 1.52 0.007
Q15436 Protein Transport Protein Sec23A (SC23A_HUMAN) 0.66 0.017
Q9NZ08 Endoplasmatic reticulum aminopeptidase 1 (ERAP1_HUMAN) 1.10 0.037
O15533 Tapasin (TPSN_HUMAN) 0.88 0.017
P51159 Ras-related protein Rab-27A (RB27A_HUMAN) 0.63 0.002
Q9Y4L1 Hypoxia up-regulated protein 1 (HYOU1_HUMAN) 1.11 0.003
P12314 High affinity immunoglobulin gamma Fc receptor I (FCGR1_HUMAN) 1.67 0.028
P05771 Protein Kinase C beta type (KPCB_HUMAN) 0.74 0.039
P61163 Alpha-centractin (ACTZ_HUMAN) 0.6 0.029
Q15836 Vesicle-associated membrane protein 3 (VAMP3_HUMAN) 1.43 0.018
O94855 Protein transport protein Sec24D (SC24D_HUMAN) 1.28 0.004
O00232 26S Proteasome non-ATPase regulatory subunit 12 (PSD12_HUMAN) 1.19 0.013
P49721 Proteasome subunit beta type-2 (PSB2_HUMAN) 0.65 0.026
P28070 Proteasome subunit beta type-4 (PSB4_HUMAN) 0.67 0.044
Antigen presentation by MHC class I and MHC class II
I
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Fig. S1: Neutrophils mimic APC-like phenotype in sepsis. 
a, Age in years for controls and sepsis patients. All values are shown as medians (n= 9 for controls, 
n= 23 for sepsis; Mann-Whitney test; ns, not significant).  
b, Body Mass Index in kg/m2 for controls and sepsis patients. All values are shown as medians (n= 
10 for controls, n= 18 for sepsis; Mann-Whitney test; ns, not significant).  
c, Polymorphonuclear cells (PMN) viability in percentage, measured with ADAM cell counter 
system. Viability was measured with ADAM Automated Cell Counter using Propidium Iodide (PI) 
staining. All values are shown as medians (n= 10 for controls, n= 12 for sepsis; Mann-Whitney test; 
ns, not significant).  
d, top Representative kinetics of ROS production (RLU/s detection over 2 hours) in response 
to in vitro Salmonella (MOI100, MOI200) and Candida stimulation (MOI2) for control and 
sepsis patient. Means and standard deviations of three technical replicas are shown.  
buttom Summary for control and sepsis patients. DPI as control was used (NADPH oxidase 
inhibitor, 10µM). All values are shown as medians (n= 18 for controls, n= 3 for sepsis; 
Mann-Whitney test; **, P< 0.01; ns, not significant).  
e, PMN-to-lymphocyte ratio (NLR) as an index for severity of disease. NLR was measured in whole 
blood with flow cytometry using CD66+ / CD3+ antibodies. All values are shown as medians (n= 9 
for controls, n= 12 for sepsis; Mann-Whitney test; ***, P< 0.001).  
f,  top List of significant protein changes involved in Antigen presentation by MHC class I from 
proteomics data analysis (n= 9 for controls, n= 10 for sepsis). Significance threshold was 
set at P-value < 0.02 and fold change £ 1.5 cut-off in order of P-value. Uniprot ID, Protein 
name (and gene name), Fold change (log2) and q-value are listed.  
middle List of significant protein changes involved in Antigen presentation by MHC class I: 
Cross-presentation from proteomics data analysis (n= 9 for controls, n= 10 for sepsis). 
Significance threshold was set at P-value < 0.02 and fold change £ 1.5 cut-off in order of P-
value. Uniprot ID, Protein name (and gene name), Fold change (log2) and q-value are 
listed.  
below List of significant protein changes involved in Antigen presentation by MHC class II 
from proteomics data analysis (n= 9 for controls, n= 10 for sepsis). Significance threshold 
was set at P-value < 0.02 and fold change £ 1.5 cut-off in order of P-value. Uniprot ID, 
Protein name (and gene name), Fold change (log2) and q-value are listed.  
g, Gene Ontology (GO) Process Enrichment from proteomics analysis on human neutrophils from 
control (n= 9) and sepsis patients (n= 10), using Metacore Enrichment by GO Processes. P-value of 
proteomics data was set < 0.05, threshold = 0, listed are the top 20 hits with an enrichment 
significance of P-value < 0.01. Identified protein counts are indicated in brackets. Red bars highlight 
Processes involved in Antigen processing and presentation in sepsis.  
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h, Gene Ontology (GO) Molecular Functions Enrichment from proteomics analysis on human 
neutrophils from control (n= 9) and sepsis patients (n= 10), using Metacore Enrichment by GO 
Molecular Functions. P-value of proteomics data was set < 0.05, threshold = 0, listed are the top 10 
hits with an enrichment significance of P-value < 0.01. Identified protein counts are indicated in 
brackets. Red bars highlight Molecular Functions involved in Antigen processing and presentation in 
sepsis, such as Peptide Antigen Binding, Peptide Binding, Antigen binding, and TAP binding.  
i, List of significant protein changes involved in Antigen presentation by MHC class I and II from 
proteomics analysis on human neutrophils (n= 9 for controls, n= 10 for sepsis). Significance 
threshold was set at P-value < 0.02 and fold change £ 1.5 cut-off in order of P-value. Uniprot ID, 
Protein name (and gene name), Fold change (log2) and q-value are listed. Target proteins were 
identified by using Metacore software analysis, Uniprot database (www.uniprot.org) and extensive 
literature research.  
j, List of significant, identified protein changes involved in Antigen presentation and processing by 
MHC class I and II in human neutrophils from control (n= 9) and sepsis patients (n= 10), shown on 
an individual level with log2 ratio, normalized (0-1) and grouped according to cellular localizations. 
Significance threshold was set at P-value < 0.02 and fold change £ 1.5 cut-off in order of P-value. 
Protein names are used according to entry names in UniProt database (www.uniprot.org). All values 
are shown as medians (Mann-Whitney test; ****, P< 0.0001; **, P< 0.001; **, P< 0.01; *, P< 0.05).  
k, HLA-DR and CD74 (Li) surface expression on human neutrophils of control and sepsis patients, 
measured with flow cytometry. Data are shown as Mean Fluorescence Intensity (MFI) and 
Percentage. All values are shown as medians (n= 10 for controls; n= 10 for sepsis; Mann-Whitney 
test; ****, P < 0.0001; **, P < 0.01).  
l, Plasma cytokine concentration for IL-1b, IL-33, IL-23, IL-17A, IL-12, IL-10, IL-8 and TNF-a of 
control (n= 10) and sepsis patients (n= 17). Concentrations are indicated in [pg/ml]. All values are 
shown as medians (Mann-Whitney test; ns, not significant; n.d., not determined, out of standard 
curve range). 
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Fig. S2: GM-CSF and IFN-g induce APC-like phenotype in human neutrophils in vitro and 
reduce neutrophil apoptosis. 
a,  top HLA-A, -B, -C expression (MFI) of viable (Annexin V-) neutrophils was measured after 
stimulation with human recombinant GM-CSF (10 ng/ml), IFN-g (10 ng/ml), IL-6 (10 ng/ml) 
and IL-18 (10 ng/ml) for 24h, pre-incubated with/ without Pan-Caspase inhibitor q.OPh 
(3µM), measured with flow cytometry. All values are shown as medians (n=2-4).  
bottom HLA-B and B2M mRNA expression after stimulation with human recombinant GM-
CSF (10 ng/ml) and IFN-g (10 ng/ml) for 4, 24 and 48h. Values are shown as relative fold 
change to unstimulated control and internal control (housekeeping gene, HK). All values are 
shown as medians (n=6).  
b, Apoptotic neutrophils (Annexin V+) were shown after stimulation with human recombinant GM-
CSF (10 ng/ml), IFN-g (10 ng/ml), IL-6 (10 ng/ml) and IL-18 (10 ng/ml) for 4h, 24h and 48h, pre-
incubated with/ without Pan-Caspase inhibitor q.OPh (3µM), measured with flow cytometry. All 
values are shown as medians (n=3-6). Percentage of HLA-DR/ -DP/ -DQ+ /Annexin V- neutrophils 
on human neutrophils (CD66b+ cells) after stimulation with human recombinant GM-CSF (10 ng/ml), 
IFN-g (10 ng/ml), IL-6 (10 ng/ml) and IL-18 (10 ng/ml) for 4h and 24h, pre-incubated with/ without 
Pan-Caspase inhibitor q.OPh (3µM), measured with flow cytometry. All values are shown as 
medians (n=3-6).  
c, Representative scatter dot plots of HLA-DR/ -DP/ -DQ and Annexin V surface expression on 
human neutrophils after stimulation with human recombinant GM-CSF (10 ng/ml) for 4h, 24h and 
48h, pre-incubated -/ + Pan-Caspase inhibitor q.OPh (3µM), measured with flow cytometry. SSC-H 
and FSC-H plot demonstrate the increasing rate of neutrophils apoptosis (controls) in vitro without 
Pan-Caspase inhibitor q.OPh addition. HLA-DR/ -DP/ -DQ and Annexin V plots underline the 
increasing rate of neutrophils apoptosis (controls) in vitro without Pan-Caspase inhibitor q.OPh 
addition, despite strict gating conditions. Red squares are highlighting the beneficial effect of Pan-
Caspase inhibitor q.OPh addition for neutrophil survival.  
d, Caspase-3/-7, Caspase-8, Caspase-9 and Pan-Caspase activity in human neutrophils was 
measured with FAM FLICATM Caspase kit. Neutrophils were pre-incubated without (green) and with 
Pan-Caspase inhibitor q.OPh (blue, 3µM) for 48h, and Caspase activity measured with flow 
cytometry. Unstained, untreated control is indicated in grey. All MFI values are shown as medians 
(n=5-6; Wilcoxon signed rank test; **, P < 0.01; *, P < 0.05).  
e, Neutrophils were pre-incubated without (green), mock control (DMSO, 1:100, dark grey), and 
selective Caspase inhibitors for Caspase-3 (C3I), Caspase-6 (C6I), Caspase-8 (C8I), Caspase-9 
(C9I), Pan-Caspase (CPanI), and with Pan-Caspase inhibitor q.OPh (blue, 3µM) for 48h, and 
apoptosis was determined with flow cytometry (Annexin V+/PI- cells). All percentages of Annexin 
V+/PI- cells are shown as medians (n=8; Wilcoxon signed rank test; **, P < 0.01).  
f, Gating strategy of a representative example of de novo MHC class II (HLA-DR/ -DP/ -DQ) surface 
molecule expression on neutrophils after stimulation with human recombinant GM-CSF (10 ng/ml) 
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respectively IFN-g (10 ng/ml) for 48h, measured by Image Stream X. The cell population gate was 
defined by the Aspect Ratio Intensity and Area, the focus was set at Gradient RMS levels > 50. 
Human neutrophils were identified as CD66+/DAPI+ cells. MHC class II expression levels were 
measured by HLA-DR/-DP/-DQ expression.  
g, Schematic overview of cytokine-induced MHC class I and MHC class II induction in human 
neutrophils in vitro. GM-CSF induces de novo MHC class II after 48h, whereas MHC class I 
expression is unaffected. IFN-g induces both, MHC class I and MHC class II expression after 24h 
and 48h, respectively. IL-18 and IL-6 neither induce MHC class I nor MHC class II expression on 
neutrophils in vitro.  	  
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Fig. S3: GM-CSF signaling leads to the activation of JAK-STAT, MAPK p38 and mTOR-AKT 
signaling pathways and phosphorylation of transcription factor CREB1. 
a, 3579 phosphopeptides were detected in human neutrophils after stimulation with GM-CSF for 
30min, belonging to 1328 phosphoproteins. Phosphoproteomics data were performed in three 
biological replica each condition. 858 significant phosphopeptide changes were identified, whereas 
466 phosphopeptides were increased and 392 phosphopeptides were decreased upon GM-CSF 
stimulation. Significance threshold was set at q-value < 0.05 and fold change £ 2 cut-off in order of 
P-value. The majority of significantly changed phosphopeptides contain a serine/threonine residue 
phosphorylation (pST, n=794), whereas tyrosine residue phosphorylation (pY, n=8) and oxidation 
(pM, n=56) were minor.  
b, Squared Pearson correlation coefficient R2 of integrated peptide feature intensities between GM-
CSF stimulation and control is 0.53.  
c, Hierarchical clustering of log10 abundance ratios of changed phosphopeptides for three biological 
replica R1-R3 each condition (GM-CSF stimulation, green; control, red).  
d, Temporal dynamics of STAT5 phosphorylation (Y694) after GM-CSF stimulation for 15, 30, 60 
and 120 min, measured by using PhosFlow antibodies for flow cytometry. Unstimulated control is 
shown in white, GM-CSF stimulation is shown shaded. Quantification of flow cytometry data with 
absolute values in MFI (mean fluorescence intensity). All values are shown as medians (n = 6; 
Wilcoxon signed rank test, *, P< 0.05; ns, not significant).  
e, Overview of hierarchical signaling phosphorylation events in human neutrophils upon GM-CSF 
stimulation in vitro. Proteins from the phosphoproteome of GM-CSF stimulated neutrophils are 
surrounded in red and filled in average-grey, additionally confirmed phosphoproteins by PhosFlow 
were surrounded in red and filled in dark-grey. Single confirmation of phosphoproteins by PhosFlow 
were were surrounded in red and filled in light-grey. JAK1/2 inhibition by Ruxolitinib inhibits all three 
different pathways. Figure was drawn with the help of Biorendor software (www.biorender.io). 
JAK1/2, Janus Kinase 1 and 2; STAT5, Signal Transducer and Activator of Transcription 5; p38, p38 
mitogen-activated protein kinase; MSK1, Mitogen- and stress-activated protein kinase-1; PI3K, 
Phosphoinositide-3-kinase; mTOR, mechanistic Target of Rapamycin; S6K1, p70 ribosomal S6 
kinase 1; AP1, Activator protein-1; RSK, p90 ribosomal S6 kinase; JNK, C-Jun-N-terminal kinase; 
RAS, Rat sarcoma protein; RAC, Rho family of GTPases; CDC42, Cell division control protein 42; 
TAK, Tat-associated kinase; MEKK, MAP kinase kinase kinase; MEK, kinase of MAP kinase; MKK, 
Mitogen-activated protein kinase kinase; ERK, Extracellular-signal regulated kinase; MK, Mitogen-
activated protein kinase 2. 
 
 
104 
	  
co
ntr
ol 
+ G
M-
CS
F
co
ntr
ol 
+ G
M-
CS
F
0.8
1.0
1.2
1.4
1.6
1.8
2.0
C
R
EB
-P
 (S
13
3)
 [r
el
at
iv
e 
fo
ld
]
control ΔH89
ns
A B
0.1
1
10
100
1000
re
la
tiv
e 
C
IIT
A 
ex
pr
es
si
on
 
to
 u
ns
tim
ul
at
ed
 a
nd
 H
K
CIITA (4h)
Ruxolitinib
GM-CSF+ - + 
+ - -
* *
co
ntr
ol 
+ G
M-
CS
F 
co
ntr
ol 
+ G
M-
CS
F 
0
20
40
60
80
H
LA
-D
R
, -
D
P,
 -D
Q
 [%
 p
os
iti
ve
 P
M
N
] 
Atorvastatin control
*
co
ntr
ol 
+ G
M-
CS
F 
co
ntr
ol 
+ G
M-
CS
F 
0
20
40
60
80
H
LA
-D
R
, -
D
P,
 -D
Q
 [%
 p
os
iti
ve
 P
M
N
] 
Lovastatincontrol
C
 
 
105 
Fig. S4: Targeting the MHC class II enhanceosome in human neutrophils. 
a, CREB1 phosphorylation at Ser133 in upon GM-CSF stimulation for 30min, pre-treated with 
inhibitor H89 (PKA inhibitor, final conc. = 10µM), was quantified with flow cytometry. Data are shown 
with relative fold changes to control (n = 10-18; Wilcoxon signed rank test; ns, not significant).  
b, CIITA mRNA expression after stimulation with human recombinant GM-CSF (10 ng/ml) for 4h, 
pretreated with Ruxolitinib (DJAK1/2 inhibitor, final conc. = 3µM) for 1h. Values are shown as 
relative fold change to unstimulated control and internal control (housekeeping genes, HK). All 
values are shown as medians (n=6; Wilcoxon signed rank test; *, P< 0.05).  
c, Percentage of HLA-DR/ -DP/ -DQ+ /Annexin V- neutrophils after pre-incubation with/ without 
Atorvastatin (DHMG-CoA reductase inhibitor, final conc. = 50µM), and Lovastatin (DHMG-CoA 
reductase inhibitor, final conc. = 50µM), stimulated with human recombinant GM-CSF (10 ng/ml) for 
48h. All values are shown as medians (n=11 for Atorvastatin, n=5 for Lovastatin; Wilcoxon signed 
rank test; *, P< 0.05). 	  
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Uniprot ID Protein
Fold Change 
(log2) P-value
P04223 H-2 class I histocompatibility antigen, K-K alpha chain (HA1K_MOUSE) 3.78 0.000
P01902 H-2 class I histocompatibility antigen, K-D alpha chain (HA1D_MOUSE) 3.27 0.000
P01897 H-2 class I histocompatibility antigen, L-D alpha chain (HA1L_MOUSE) 2.71 0.000
P01900 H-2 class I histocompatibility antigen, D-D alpha chain (HA12_MOUSE) 1.87 0.000
P04228 H-2 class II histocompatibility antigen, A-D alpha chain (HA2D_MOUSE) 0.79 0.039*
P01887 Beta-2-microglobulin (B2MG_MOUSE) 2.26 0.003
P97371 Proteasome activator complex subunit 1 (PMSE1_MOUSE) 1.29 0.005
P97372 Proteasome activator complex subunit 2 (PMSE2_MOUSE) 1.29 0.002
Q9R1P3 Proteasome subunit beta type-2 (PSB2_MOUSE) 1.66 0.001
P28076 Proteasome subunit beta type-9 (PSB9_MOUSE) 1.64 0.001
O35955 Proteasome subunit beta type-10 (PSB10_MOUSE) 2.25 0.000
P21958 Antigen peptide transporter 1 (TAP1_MOUSE) 2.98 0.000
P36371 Antigen peptide transporter 2 (TAP2_MOUSE) 2.23 0.001
Q9R233 Tapasin (TPSN_MOUSE) 2.91 0.000
Q8VD31 Tapasin-related protein (TPSNR_MOUSE) 2.83 0.000
P08113 Endoplasmin (ENPL_MOUSE) 1.49 0.003
Q9EQH2 Endoplasmic reticulum aminopeptidase 1 (ERAP1_MOUSE) 2.26 0.000
P14211 Calreticulin (CALR_MOUSE) 0.91 0.013
P11499 Heat shock protein HSP 90-beta (HS90B_MOUSE) 1.10 0.006
P22366 Myeloid differentiation primary response protein MyD88 (MyD88_MOUSE) 1.13 0.008
Q61699 Heat shock protein 105 kDa (HS105_MOUSE) 1.15 0.008
Q6QLQ4 C-type lectin domain family 7 member A, Synoyme: Dectin-1 (CLC7A_MOUSE) -2.4 0.000
O70370 Cathepsin S (CATS_MOUSE) 2.82 0.000
P18242 Cathepsin D (CATD_MOUSE) 0.82 0.010
Q9WUU7 Cathepsin Z  (CATZ_MOUSE) 0.95 0.015
E
Antigen presentation by MHC class I and MHC class II (n=25)
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Gene	ID	
(_MOUSE	 or	_HUMAN) Protein	Name Regulation	HUMAN Regulation	MOUSE Function
RL5 60S	ribomal protein	L5 Up Up Ribosome
RPN1 Dolichyl-diphphooligaccharide--protein	 glycyltransferase subunit	1 Up Up
SSRA Translocon-associated	 protein	subunit	alpha	 Up Up
PACS1 Phphofurin	 acidic	cluster	sorting	protein	1	 Down Down
MLEC Malectin	 Up Up
ETFA Electron	transfer	flavoprotein	subunit	alpha,	mitochondrial	 Up Up Mitochodrion
ACADM Medium-chain	 specific	 acyl-CoA	dehydrogenase,	mitochondrial	 Up Up Mitochodrion
ARSB Arylsulfatase	B	 Down Up
HYOU1 Hypoxia	up-regulated	protein	1	 Up Up Antigen	processing	and	presentation
CASP1 Caspase-1	 Up Up Interferon	Signaling
CAMP Cathelin-related	antimicrobial	peptide	 Down Down
COX41 Cytochrome	 c	oxidase	subunit	 4	isoform	1,	mitochondrial	 Up Up Mitochondrion/	 Apoptose
ACSL1 Long-chain-fatty-acid--CoA	 ligase	1	 Up Up
DHB4 Peroxisomal multifunctional	 enzyme	type	2	 Up Up
HS105 Heat	shock	protein	105	kDa Up Up Antigen	processing	and	presentation
ELAV1 ELAV-like	protein	1	 Up Up
IFIT2 Interferon-induced	 protein	with	tetratricopeptide repeats	2	 Up Up Interferon	Signaling
STT3A Dolichyl-diphphooligaccharide--protein	 glycyltransferase	subunit	STT3A	 Up Up
LCP2 Lymphocyte	 cytolic	protein	2	 Up Up
PDIA1 Protein	disulfide-isomerase	 Up Up
PADI4 Protein-arginine	deiminase	type-4	 Down Down
PROP Properdin	 Down Down
PPT1 Palmitoyl-protein	thioesterase	1	 Up Up
PSB4 Proteasome	subunit	 beta	type-4	 Up Up Antigen	processing	and	presentation
RL30 60S	ribomal	protein	L30	 Up Up Ribosome
RS18 40S	ribomal	protein	S18	 Up Up Ribosome
TAP1 Antigen	peptide	transporter	1	 Up Up Antigen	processing	and	presentation
TPSN Tapasin	 Up Up Antigen	processing	and	presentation
CKAP4 Cytkeleton-associated	protein	4	 Up Up
TIAR Nucleolysin TIAR	 Up Up
ENPL Endoplasmin Up Up Antigen	processing	and	presentation
GBP5 Guanylate-binding	protein	5	 Up Up Interferon	Signaling
PTBP3 Polypyrimidine tract-binding	protein	3	 Up Up
EFTU Elongation	factor	Tu,	mitochondrial	 Up Up
OAS3 2'-5'-oligoadenylate	synthase	3	 Up Up Interferon	Signaling
PSB2 Proteasome	subunit	 beta	type-2	 Up Up Antigen	processing	and	presentation
AAK1 AP2-associated	protein	kinase	1	 Up Up
PAR14 Poly	[ADP-ribe]	polymerase	14	 Up Up
SND1 Staphylococcal	nuclease	 domain-containing	 protein	1	 Up Up
NAMPT Nicotinamide	 phphoribyltransferase	 Up Up
NIBAN Protein	Niban	 Up Down
NMI N-myc-interactor	 Up Up
EF1D Elongation	factor	1-delta	 Up Up Ribosome
RS20 40S	ribomal	protein	S20	 Up Up Ribosome
TMCO1 Transmembrane	 and	coiled-coil	 domain-containing	 protein	1	 Up Up
PDIA6 Protein	disulfide-isomerase	 A6	 Up Up
RS25 40S	ribomal	protein	S25	 Up Up Ribosome
CKAP5 Cytkeleton-associated	protein	5	 Up Up
MBOA7 Lysophpholipid	 acyltransferase	7	 Up Up
MVP Major	vault	protein	 Up Up
ERAP1 Endoplasmic	 reticulum	aminopeptidase	 1	 Up Up Antigen	processing	and	presentation
RRBP1 Ribome-binding	 protein	1	 Up Up Ribosome
LRC59 Leucine-rich	 repeat-containing	protein	59	 Up Up
F
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Fig. S5: Induction of APC-like neutrophils in a systemic Salmonella mouse model mimicking 
human typhoid fever. 
a, left Squared Pearson correlation coefficient R2 of integrated peptide feature intensities between 
non-infected and Salmonella enterica serovar Typhimurium SL1344 infected splenic neutrophils 
at day 4 is 0.88.  
right Hierarchical clustering of log2 abundance ratios of changed peptides for three biological 
replica R1-R3 each condition (non-infected, green; infected, red).  
b,  left Number of peptides (n=2223) identified by murine neutrophil proteomics from non-infected 
(n=3) and Salmonella enterica serovar Typhimurium SL1344 infected splenic neutrophils (n=3) 
at day 4 with significant increased (n=503) and decreased (n=92) peptide levels. Significance 
threshold was set at P-value < 0.03.  
right Volcano dot plot from murine neutrophil proteomics from non-infected (n=3) and 
Salmonella enterica serovar Typhimurium SL1344 infected splenic neutrophils (n=3) at day 4. 
Highlighted proteins (red dots) are associated with Antigen presentation and processing by MHC 
class I and II, significance threshold (dotted line) was set at P-value < 0.03 and fold change £ 
1.5 cut-off in order of P-value.  
c, Enriched pathways using murine neutrophil proteomics from non-infected (n=3) and Salmonella 
enterica serovar Typhimurium SL1344 infected splenic neutrophils (n=3) at day 4, using Metacore 
Enrichment by Pathway Maps. P-value of proteomics data was set < 0.05, threshold = 0, listed are the 
top 20 hits with an enrichment significance of P-value < 0.01. Identified protein counts are indicated in 
brackets. Red bars highlight Antigen Presentation and processing by MHC class I and MHC class II as 
highly changed pathways upon Salmonella enterica serovar Typhimurium SL1344 infection.  
d, Gene Ontology (GO) Molecular Functions Enrichment using murine neutrophil proteomics from non-
infected (n=3) and Salmonella enterica serovar Typhimurium SL1344 infected splenic neutrophils (n=3) 
at day 4, using Metacore Enrichment by GO Molecular Functions. P-value of proteomics data was set < 
0.05, threshold > 1, listed are the top 10 hits with an enrichment significance of P-value < 0.01. Identified 
protein counts are indicated in brackets. Red bars highlight Molecular Functions involved in Antigen 
processing and presentation upon Salmonella enterica serovar Typhimurium SL1344 infection, such as 
TAP binding, Peptide antigen-transporting ATPase activity, MHC protein binding, TAP2 binding, TAP1 
binding, and MHC class I protein binding.  
e, List of significant protein changes involved in Antigen presentation by MHC class I and II from 
proteomics data analysis (n=3 for non-infected, n= 3 for infected). Significance threshold was set at P-
value < 0.03 and fold change £ 1.5 cut-off in order of P-value. Uniprot ID, Protein name (and gene 
name), Fold change (log2) and P-value are listed.  
f, List of significantly differentially expressed, orthologous proteins by comparing the proteome data sets 
from isolated splenic murine neutrophils infected with Salmonella enterica serovar Typhimurium at day 4 
and the human peripheral blood derived neutrophils in sepsis (n=52, FDR< 0.05). Gene ID, protein 
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name, regulation in human and mice and function are listed. Around 15% of those identified proteins are 
involved in antigen processing and presentation (n=8). 
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5.3 Immune Reconstitution After Allogeneic Hematopoietic Stem Cell 
Transplantation and Association with Occurrence and Outcome of Invasive 
Aspergillosis 
 
Stuehler C1, Kuenzli E2, Jaeger VK3, Baettig V2, Ferracin F1, Rajacic Z1, Kaiser D1, 
Bernardini C1, Forrer P1, Weisser M2, Elzi L2, Battegay M2, Halter J4, Passweg J4, Khanna 
N1,2 * 
 
1Infection Biology Laboratory, Department of Biomedicine; 2Division of Infectious Diseases 
and Hospital Epidemiology, Department of Clinical Research; 3Department of 
Rheumatology; 4Division of Hematology, University Hospital of Basel, Switzerland.   
* Corresponding author 
 
Manuscript has been published in The Journal of Infectious Diseases, 2015; 212:959-67 
DOI: 10.1093/infdis/jiv143 
 
Statement of my work:  
Design of experiments 
ROS production assays + Analysis (partly contributed to Fig. 2A; Fig. 4A; Fig. 5A, but Fig. 
6 is not shown in the paper). 
Note: The following part contains only the abstract and the figures to which I contributed in 
this manuscript. The contribution of my work is the establishment and optimization of the 
chemiluminescence-enhanced ROS production assay and the finding that isolated 
neutrophils have to be processed as soon as possible because of cellular apoptosis.  
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5.3.1 Abstract/ Summary  
Invasive aspergillosis (IA) remains a leading cause of morbidity and mortality in patients 
receiving allogeneic hematopoietic stem cell transplantation (HSCT). This infection occurs 
either early posttransplantation during neutropenia or late due to graft-versus-host disease 
(GVHD) and the required immunosuppressive treatment. 
Antifungal prophylaxis or treatment in high-risk patients is often ineffective due to impaired 
host immunity and is furthermore associated with drug interactions, emergence of resistant 
fungi, toxicity, and high costs. Immune surrogate markers such as CD4+ cell counts in 
human immunodeficiency virus–infected individuals and cytomegalovirus (CMV)–specific 
cell-mediated immunity in solid organ transplantation to guide treatment have not been 
established for patients with IA. 
Innate immune cells, including macrophages and polymorphonuclear cells (PMNs), are key 
players to control fungal invasion. PMNs possess an array of effector functions involving 
reactive oxygen species (ROS)–dependent and independent killing mechanisms. 
T cells, particularly CD4+ memory T cells, specific for different Aspergillus antigens can be 
detected in the peripheral blood of healthy individuals and HSCT recipients. In general, T 
helper (TH)1 and potentially TH17 cytokines are considered to confer protective immunity 
against Aspergillus, whereas TH2 responses are deleterious. Furthermore, recent studies 
suggest that natural killer (NK) cells are crucial for fungal clearance. 
So far, specific reconstitution of antifungal immune responses in patients after HSCT with 
and without IA has not been investigated in detail. The purpose of this study was to 
prospectively follow patients after HSCT and to obtain comprehensive data on immune 
reconstitution and the functionality of PMNs, NK cells, different TH subsets, and CD8+ T 
cells in order to characterize susceptibility of these patients to IA and to identify possible 
biomarkers to guide antifungal treatment. 
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Fig. 6: IFN-γ enhances ROS production in response to C. albicans in healthy individuals.
A, Example plot for ROS production (RLU/s) by PMNs after stimulation with heat-inactivated C. albicans yeasts with 
and without IFN-γ priming for 3h. Data are shown in triplicates for C. albicans yeast stimulation over 120 min. B, 
Maximun release of ROS (RLU/s) by PMNs after stimulation with heat-inactivated C. albicans yeasts with and without 
IFN-γ priming for 1h, 3h, 5h and overnight (ON). RLU, relative light unit. All values are shown as medians (n=9; 
Wilcoxon signed rank test; **, P< 0.01).
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5.4 Fatty acid oxidation modulates ROS and cytokine production by Ly6Chi 
inflammatory monocytes in sepsis 
 
Mauricio Rosas-Ballina1*, Nura Schürmann1, Pascal Forrer2, Beatrice Claudi1, Olivier 
Cunrath1, Thomas Bock3, Janine Zankl4, Alexander Schmidt3, Nina Khanna2,5, Giuseppe 
Danilo Norata6, Dirk Bumann1*. 
 
1 Focal Area Infection Biology, Biozentrum, University of Basel, 4056 Basel, Switzerland; 2 
Infection Biology Laboratory, Department of Biomedicine, University of Basel, 4031 Basel, 
Switzerland; 3 Proteomics Core Facility, Biozentrum, University of Basel, Switzerland; 4 
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Infectious Diseases and Hospital Epidemiology, Department of Clinical Research, 
University Hospital of Basel, 4031 Basel, Switzerland; 6 Department of Pharmacological 
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* Corresponding authors 
 
Manuscript is ready for submission.  
 
Statement of my work:  
Design of experiments, Performing experiments, Data analysis.  
Responsible clinical study manager; Writing patient study protocol; Submission of study-
related documents to Ethics Committee EKNZ; Patient recruitment and coding; Immune 
cell isolation (Fig. 4A; Fig. 5A) 
Note: The following part contains only the abstract to which I contributed in this manuscript. 
The contribution of my work is the planning, conducting and execution of the clinical study 
BASEC 2016-00676.  
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5.4.1 Abstract/ Summary 
Systemic and cellular metabolic derangements are known components of the dysregulated 
host response to infection. However, how systemic lipid metabolism integrates with 
immune cell function to mediate phagocyte pro-inflammatory function in sepsis remains to 
be explored. Here we show that mice infected with Salmonella course with a pro-
atherogenic state defined by increased low-density lipoprotein (LDL)-cholesterol plasma 
levels accompanied by neutral lipid accumulation in circulating and spleen inflammatory 
monocytes and neutrophils. Surprisingly, spleen inflammatory monocytes from septic mice 
had a pro-inflammatory phenotype with elevated ROS levels, and increased TNF and IL-1β 
mRNA levels despite a higher oxygen consumption rate driven by mitochondrial fatty acid 
oxidation, a metabolic feature of M2 anti-inflammatory activation in vitro. Further, a single 
dose of the beta-oxidation inhibitor etomoxir to septic mice increased neutral lipid and 
reduced total cellular ROS, TNF, and IL-1β levels in spleen inflammatory monocytes but 
worsened disease progression due to off-target effects on liver. Finally, monocytes from 
patients with gram-negative bacteremia contained higher neutral lipid content compared to 
age-, gender-, and body mass index-matched controls while ex vivo treatment with 
etomoxir reduced ROS levels in monocytes of patients and controls. Our results unravel a 
lipid metabolic program in sepsis common to atherosclerosis and put forth targeted 
inhibition of fatty acid oxidation in monocytes as a therapeutic approach against sepsis. 
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6 Discussion 
Pathogen clearance in infectious diseases strongly depends on efficient innate and 
adaptive immune responses. We showed that “simple foot soldier” neutrophils are 
important for host defense against bacterial and fungal pathogens. With the help of two key 
enzymes, the NADPH oxidase and MPO, neutrophils are able to produce large amounts of 
ROS that are important for pathogen destruction. However, excessive ROS can also cause 
detrimental damage in host tissues. We showed that MPO has a protective role in the host 
by scavenging diffusible H2O2 at the Salmonella surface and converting it into highly 
reactive HOCl within a short reach. Hence, MPO confines potential harmful molecules to 
the pathogen microenvironment without causing collateral host tissue damage.  
Neutrophils as “versatile commanders” are unambiguously involved in the pathogenesis of 
sepsis, the dysregulated host response to infection. We identified a subset of APC-like 
neutrophils with MHC class II molecule expression, which could be induced under 
inflammatory conditions. We could show that the MHC class II enhanceosome is 
responsible for the subsequent MHC class II expression on neutrophils and that targeting 
JAK1/2 kinase could be a promising therapeutic approach in sepsis to reach cellular 
homeostasis. Overall, we conclude that infectious disease control implies a specialized, but 
versatile immune system with diverse neutrophil functionality. 
6.1 Neutrophils as simple foot soldiers of immunity in infectious diseases 
Neutrophils are potent phagocytic cells that efficiently eradicate pathogens by using 
oxidative and non-oxidative killing mechanisms. The oxidative killing mechanism is strongly 
dependent on two key enzymes, the NADPH oxidase and MPO. Together, they produce 
large amounts of ROS that are lethal for pathogens. Previous reports could clearly 
demonstrate that NADPH oxidase deficiency leads to high pathogen load in organs in a 
mouse model of Salmonellosis and impaired Salmonella killing by neutrophils and 
inflammatory monocytes compared to wildtype mice 288. However, the role of MPO in 
systemic Salmonella infection is entirely unclear. It is known that MPO converts almost all 
O2- or H2O2 into highly toxic hypohalous acids (OCl-, OBr-, OF- or OI-) with predominant 
HOCl production. HOCl is a highly reactive oxidant with potent antimicrobial efficacy 49 in 
somehow artificial cell culture systems. In vivo, data from both individuals and mice with 
MPO deficiency in infections were inconclusive. For that reason, we combined a 
computational modelling approach based on in vivo and in vitro data to elucidate the role of 
ROS and MPO in Salmonella infection. 
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Our data showed that during Salmonella infection, MPO co-localized mainly to deceased 
pathogen surface in vivo. This finding is strongly supporting the direct contribution of the 
MPO-mediated product HOCl in Salmonella killing. On the contrary, our data from MPO 
deficient mice revealed only slightly elevated levels of pathogen tissue load compared to 
wildtype mice, supporting the idea of compensatory MPO-independent killing mechanisms 
in vivo with other ROS release than HOCl or enhanced non-oxidative killing mechanisms. 
In our model, we implemented published data from a computational model of oxidative 
bursts in neutrophil phagosomes 66 with in vivo data from ROS defense in Salmonella 
enterica serovar Typhimurium 288. We predicted that H2O2 levels accumulate in the 
Salmonella cytosol up to 15 µM in the absence of MPO. Lethality threshold was estimated 
around 2 µM 289, as reported by another group showing similar H2O2-induced lethality 
concentrations in E. coli 290. Nevertheless, our data are contrary to the results found by 
Winterbourne et al. 66 They proposed an intraphagosomal accumulation of non-lethal levels 
of H2O2 up to 30 µM in the absence of MPO. Despite these discrepancies, our data clearly 
showed that Salmonella are eradicated either by MPO-derived HOCl if MPO is present or 
that Salmonella is killed by high, lethal levels of H2O2 in the absence of MPO.   
MPO is it the most abundant granule protein in neutrophils 291, synthesised in daily 
amounts of hundreds of milligrams 49. If MPO has a redundant function in pathogen killing, 
why does the cell invest high costs to produce it? We postulated that MPO has an 
important function in mitigating collateral tissue damage during oxidative stress exposure. 
In general, ROS production during antimicrobial host defense bears an enormous potential 
to damage host tissues. Therefore, precision guidance of ROS fluxes towards the 
pathogen is indispensable. MPO converts diffusible long-lived H2O2 into highly reactive, 
toxic and locally confined HOCl at the pathogen surface. Our computational model data 
could predict that the less MPO available in the phagosome, the less HOCl production and 
the higher the H2O2 accumulation in the neutrophil phagosome. Since the buffering 
capacity of the cell is limited to some extent, H2O2 leakage out of the phagosome and out 
of the host cell occurs at substantial rates. Our results are opposite to Winterbourne et al. 
They suggested that H2O2 leakage out of the cell can be scavenged by neutrophil 
protection mechanisms such as glutathion peroxidases 66, which is supported by the fact 
that neutrophils are known to be the most resistant cell type against exogenous H2O2 292. 
However, this assumption is based on in vitro studies using MPO-deficient neutrophils that 
did not reveal increased accumulation of H2O2, but elevated levels of O2- in neutrophils 
during the first few minutes of oxidative burst 293. Thus, we re-examined this question by 
using pharmacological MPO inhibition and MPO deficient human neutrophils with longer 
stimulation time and specific assays to detect O2- production, H2O2 release, MPO activity 
and HOCl production. We could confirm our predicted computational modelling data by 
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showing that MPO deficient neutrophils release higher levels of H2O2, and not O2-, during 
oxidative bursts with experimental in vitro data. Moreover, our in vivo experiments with 
MPO deficient mice infected with Salmonella showed elevated levels of H2O2 in tissues and 
oxidative damage of lipids and DNA. In summary, we strongly assume that upon 
Salmonella infection, the pharmacological MPO inhibition and MPO deficiency in 
neutrophils leads to massive accumulation of H2O2 in the phagosome and subsequent H2O2 
release to the extracellular space, without deficits in intracellular pathogen killing, but with 
collateral tissue damage. 
Some reports could show that MPO deficiency in vivo results in enhanced chemokine 
expression and additional neutrophil recruitment in several mouse models 294-297. Hence, 
increased oxidative tissue damage in MPO deficient mice could result from increased 
neutrophil recruitment producing higher ROS levels in sum rather than H2O2 leakage into 
the extracellular space per se. However, our tissue staining for CD11b (marker for 
inflammatory cells) and Ly6G (neutrophils) demonstrated similar immune cell recruitment in 
MPO deficient and wildtype animals in vivo. In agreement, human whole blood 
differentiation plots from healthy and MPO deficient individuals showed similar leukocyte 
cell counts. We conclude that in our chosen in vivo model system, there is no apparent 
neutrophil recruitment amplification loop. 
Unfortunately, we were not able to show elevated H2O2-mediated tissue damage with 
pharmacologically inhibited MPO in stimulated, human neutrophils, co-cultivated with three 
different cells types (Jurkat T cells, L292 mouse fibroblasts and autologous PBMCs). We 
tested for different time points of co-incubation, several stimuli (Candida, Salmonella and 
PMA) with various MOI, various target cell numbers, various effector-to-target cell ratios 
and different media with/without supplements in vitro. Although we could induce tissue 
damage/ toxicity by using very high and somehow artificial levels of H2O2 (in range of mM) 
in vitro, in agreement with reports that showed rather high doses of H2O2 required for 
bacterial killing 298 and tissue damage, respectively 299-301. Most of these studies using high 
doses referred to bolus injections of H2O2 into the medium (of which only a fraction 
penetrates into the bacterial cytosol and this fraction is further reduced by potent 
Salmonella detoxification mechanisms). Moreover, commonly used and non-physiological 
bolus injections of high amounts of H2O2 are much less effective in killing compared to 
continuous H2O2 exposure because they block metabolism and limit toxic Fenton reaction, 
rendering bacteria much less vulnerable to oxidative damage 290.  
Recently, Reber et al. showed that neutrophils contribute to host protection by limiting LPS-
induced inflammation in a MPO-dependent manner 302. They speculate that anomalous 
ROS generation, namely H2O2 production, could contribute to exacerbated systemic 
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inflammation in MPO-deficient mice. However, it is unaddressed whether H2O2 -induced 
systemic inflammation directly induces lipid peroxidation and DNA damage or vice versa. 
Furthermore, our in vivo Salmonella infection model did not show visible differences in 
terms of excessive inflammation and improved survival between MPO-deficient and 
wildtype mice. 
Conclusively, we propose that MPO confines the lethal ROS fluxes locally to pathogens 
and ensures oxidative stress compartmentalized inside neutrophils phagosomes. With this 
elegant self-protective mechanism, inflammatory collateral tissue damage during 
Salmonella infection is lowered as good as possible and the primary objective, pathogen 
destruction, is even so executed as desired.  
6.2 Neutrophils as versatile commanders of immunity in infectious diseases 
Please find an extended discussion in the results section of the thesis under “APC-like 
neutrophils contribute to sepsis pathology and activate T-cell responses”. 	  
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7 Outlook 
7.1 Neutrophils as simple foot soldiers of immunity in infectious diseases  
We could demonstrate that neutrophils use their most abundant granule protein, MPO, to 
confine lethal oxidative stress into phagosomes during antimicrobial attack. This self-
protective mechanism reduces collateral host tissue damage during Salmonella infection 
and supports efficient pathogen clearance.  
 
To understand the MPO-mediated host tissue damage in in a systemic Salmonella 
infection mouse model 
A recent report has complemented the concept of MPO-mediated host protection by 
limiting LPS-induced inflammation 302. It would be interesting to know whether H2O2 -
induced systemic inflammation induces lipid peroxidation and DNA damage or vice versa. 
Therefore, future experiments could investigate the temporal tissue cytokine profile around 
DNA damage and lipid peroxidation lesions, respectively. Moreover, it would be of interest 
to identify the local influence of aberrant H2O2 levels on bystander immune cells in the 
regulation of antimicrobial and inflammatory immune responses in MPO-deficient mice.  
 
To understand the epidemiology of human MPO deficiency and monitor the clinical 
indications associated with MPO deficiency   
Epidemiological studies on MPO deficiency are scarce. As we discussed in our paper, 
early studies have reported an increased cancer incidence in patients with complete MPO 
deficiency 58. Our findings from MPO-deficient mice in a systemic Salmonella infection 
model showed collateral tissue damage with high lipid peroxidation and DNA oxidation. 
Thus, our data support the possibility that individuals with full MPO deficiency might have 
an increased risk to develop cancer if continuously exposed to pathogens. However, 
repeated human infections in immunocompetent individuals in industrialized countries are 
rare nowadays 303. Thus, lifetime impact of MPO deficiency in infectious diseases is 
potentially underestimated. It would be interesting to classify human MPO deficiency as a 
global primary immunodeficiency with the aim to monitor the prevalence of MPO deficiency 
across different countries, to differentiate partial from full MPO deficiency and associate 
those MPO levels with clinical indications such as cancer, recurrent infectious disease 
complications and cardiovascular diseases. Future work will be needed to fully assess the 
impact of the MPO-mediated protective mechanism in humans and mice. 
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7.2 Neutrophils as versatile commanders of immunity in infectious diseases  
 
To understand the dysregulated immunity in neutrophils, monocytes and 
lymphocytes during the hyperinflammatory and immunosuppressive phase in human 
sepsis 
In our work, we could demonstrate that human neutrophils show an APC-like phenotype 
with elevated MHC class I and de novo induced MHC class II expression in the pro-
inflammatory phase of sepsis. It would be interesting to extend the study design to identify 
immune-metabolic changes in neutrophils, monocytes and lymphocytes during the 
immunosuppressive phase of sepsis to get a comprehensive overview of dysregulated 
immunity during sepsis. For these reasons, we will consider to amend the study protocol in 
agreement with the responsible Ethics Committee. This research project will be a 
translational, single center, unblinded, case-control study project with five consecutive 
blood drawing events (day 0, day 2-3, day 5-7, day 10-14 and before discharge from 
hospital) aiming at identifying immune-metabolic changes in host immunity during 
hyperinflammatory phase (day 0) and immunosuppressive phase (day 5-7) in patients 
suffering from gram-negative sepsis compared to healthy, age-matched (+/- 5 years) and 
gender-matched control group. Plasma samples will be analyzed for total cholesterol, 
triacylglycerol, free fatty acids, apolipoprotein (apo)-B, and apo-AI levels to identify lipid 
metabolic changes. Plasma cytokine levels will be determined with Human Custom 
Inflammation Panel Kits for IL-1β, IFN-α, IFN-γ, TNF-α, GM-CSF, IL-6, IL-8 (CXCL8), IL-10, 
IL-12p70, IL-17A, IL-18, IL-23, and IL-33. Neutrophils, monocytes, and lymphocytes will be 
characterized in greater detail. Neutrophils and monocytes will be used to identify MHC 
class I and II, costimulatory molecules and activation marker (multi-color flow cytometry for 
HLA-DR, HLA-DR/DP/DQ, Li, CD80, CD86, CD40, HLA-A/B/C, CD83, CD54, CD11c, 
CXCR4, CD62L, CD14, CD66b, CD11b, PD-1L), quantitative proteomics (liquid 
chromatography-tandem mass spectrometry) and for oxygen consumption rate analysis 
(Seahorse cell metabolism analyzers). Monocytes will be used for total RNA isolation. 
Lymphocytes will be analyzed for phenotype (CD3, CD4, CD8, CD56, CD16, CD19), for T-
cell subsets (CD3, CD4, FoxP3, CD127 and CD25), T-cell cytokine response after 
stimulation with anti-CD3/CD28 (IFN-γ, IL-4, IL-10, IL-2, GM-CSF and TNF-α production), 
T-cell cytotoxicity (Perforin, Granzyme B, Granulysin), T-cell proliferation (CFSE staining) 
and T-cell exhaustion (PD-1, TIM-3, CTLA-4). In order to determine neutral lipid content, 
leukocytes will be stained with the fluorescent dye LipidTox. For determination of reactive 
oxygen species levels, another set of samples will be stained with the fluorescent dye 
CellRox.  
 
 
123 
Moreover, one could extend the study arms to severity classes such as Bacteremia, Sepsis 
and Septic Shock with arms sizes of n=20. Results from such a study might provide 
insights into the pathogenesis of sepsis and identify immunological biomarkers, which 
could contribute to the development of novel therapeutic approaches for the treatment of 
this potentially lethal disease.  
 
To understand the dynamic phosphoproteome signaling in human neutrophils after 
priming with GM-CSF and IFN-γ and pharmacological inhibition with ruxolitinib 
(JAK1/2 inhibitor) 
Our results showed that GM-CSF stimulation in neutrophils alters the phosphorylation of a 
complex network of proteins involved in 3 major signaling pathways, the JAK-STAT, the 
MAPK and the PI3K-Akt-mTOR pathways with overrepresented MAPK kinase activity and 
a central JAK1/2 kinase orchestrating the broad downstream protein phosphorylation. 
However, we only considered neutrophils priming with GM-CSF after 30 minutes of 
stimulation. It would be very interesting to test dynamic phosphoproteome changes upon 
GM-CSF and IFN-γ priming, as previously shown for insulin signalling in adipocytes 305, 
and elaborate differences and connections of protein phosphorylation networks among 
these two cytokines. Moreover, it would be interesting to figure out the central role of 
JAK1/2 kinase-mediated protein phosphorylation in neutrophils upon GM-CSF priming by 
using inhibitors selective against JAK1/2 kinase (Ruxolitinib) and a large systems-level 
proteomics approach. 
 
To understand the physiological relevance of APC-like neutrophils in a systemic 
Salmonella infection mouse model 
Our in vivo data substantiate the suitability of the systemic salmonellosis mouse model as 
appropriate model to study bacterial sepsis and confirm the induction of APC-like 
neutrophils during sepsis, reflecting the vast heterogeneity and diversity of neutrophils 
under inflammatory conditions. However, there remains a major open question: What is the 
physiological relevance of APC-like neutrophils in systemic Salmonella infection?  
To answer this question, we are aiming to generate a novel transgenic mouse strain with 
neutrophil-restricted deficiencies in MHC class II. Thus, we will cross MHCclassIIfl mice 
(provided by Prof. Dr. Daniela Finke group 306) to the Catchup mouse (C57BL/6-
Ly6g(tm2621(Cre-tdTomato)Arte), generated by Prof. Dr. Matthias Gunzer group 307) with 
the help of Cre/loxP recombination system and gene targeting, which should show target-
oriented deletions in neutrophils for MHC class II. Other conceivable approaches such as 
using neutrophil-depleting agents 142,308 or neutrophil-depleting systems 302 cannot properly 
answer this key question.  
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It is known that neutrophil-depleted mice are more susceptible to Salmonella infection than 
wildtype mice 308  and these mice show impaired Salmonella killing by neutrophils. 
However, neutrophil depletion approaches are not targeting MHC class II+ neutrophils in 
particular and other potent antimicrobial neutrophil effector functions such as phagocytosis, 
ROS production, degranulation, NETosis and cytokine production are biasing the 
interpretation of the experimental data. 
Moreover, mice deficient in MHC class II are affecting all APCs and suffer from severe 
immunodeficiency 143 and using MHC classIIfl mice crossing to mice expressing Cre under 
control of the murine lysozyme M gene promotor (LysMCre mice) will target MHC class II 
expression of all myeloid lineage cells, such as monocytes, macrophages and neutrophils 309. 
Recently described, even brain neurons of the central nervous system could be affected by 
this cell type-unspecific system 310. I conclude that crossing MHCclassIIfl mice to the 
Catchup mouse with the help of Cre/loxP recombination system will be the best approach 
to elaborate the physiological relevance of APC-like neutrophils in Salmonella mouse 
infection models. 
 
To understand the interplay between APC-like neutrophils and T-cell responses in a 
systemic Salmonella infection mouse model 
To answer the question, whether APC-like neutrophils activate or suppress T-cell responses in 
Salmonella infections, we will use the help from the transgenic mice above. Previous studies 
from other groups have shown that APC-like neutrophils are able to present OVA peptide to 
OVA-specific T cells and induce T-cell activation and proliferation 160,162. As the Salmonella 
mouse model induces a robust CD4+ TH1 response 311, this model is well suited to 
investigate the interaction of MHC class II positive neutrophils with CD4+ T cells in vivo in 
the context of a complex bacterial infection. 
So far, our experiments were performed in C57BL/6 mice infected i.v. with Salmonella 
strains derived from Salmonella enterica serovar Typhimurium SL1344 hisG rpsL xyl 274,275. 
However, since mice infected with wildtype Salmonella enterica serovar Typhimurium 
strain SL1344 succumb to this infection model within a few days and adaptive T-cell 
responses typically peak 7-15 days after initial antigen stimulation 304, we will optimize the 
mouse infection model. It has been shown by other groups, that vaccination of mice with 
attenuated Salmonella strains (SL1344ΔaroA312) will lead to a long-lasting T-cell memory 
and protection against re-challenge with wildtype Salmonella enterica serovar Typhimurium 
strain SL1344313,314. Thus, we hypothesize that during the secondary response to 
Salmonella enterica serovar Typhimurium strain SL1344, APC-like neutrophils in infected 
tissues might be involved in activation or suppression of tissue-resident Salmonella-specific 
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memory T cells generated during the primary infection with Salmonella enterica serovar 
Typhimurium strain SL1344 ΔaroA. To test this hypothesis, we plan to rechallenge mice 
previously infected with attenuated Salmonella enterica serovar Typhimurium strain 
SL1344ΔaroA for 40 days later with wildtype Salmonella enterica serovar Typhimurium 
strain SL1344 and we will analyse the immune cell infiltrates for APC-like neutrophils 
(CD11b+, Ly6G+, Ly6C+, I-A/I-E+) and memory T cells (CD3, CD4, CD44, CD62, CCR7, 
intracellular IFN-γ, TNF-α, GM-CSF and IL-2315) by flow cytometry. To determine the 
course of T-cell activation over time, we will analyse T-cell activation surface markers 
(CD69, CD11a, CD49d, CD44, CD62L, CD29, CD54) at different time points during the 
experiments. For those time points and organs that show the best conditions, namely the 
presence of APC-like neutrophils as well as T-cell activation, we will visualize a potential 
co-localization of APC-like neutrophils and CD4+ T-cells by immunohistochemistry. We 
further plan to isolate APC-like neutrophils from single cell suspensions of different organs 
of infected mice by fluorescence activated cell sorting and to test ex vivo if these cells are 
able to trigger T-cell responses (CD69, CD11a, CD49d, CD44, CD62L, CD29, CD54, 
CFSE staining) of isolated peripheral blood T cells from uninfected mice.  
 
To understand the selective influence of GM-CSF and IFN-γ on APC-like neutrophil 
induction in a systemic Salmonella infection mouse model 
We could show that the pro-inflammatory cytokines GM-CSF and IFN-g can induce de novo 
expression of MHC class II on mature neutrophils in vitro. However, it would be interesting 
to test those findings in the Salmonella mouse model in vivo. IFN-γ- deficient 316,317 and 
GM-CSF-deficient mice 318 are more susceptible to Salmonella infection than wildtype mice 
and in vivo treatment with a blocking anti-IFN-γ antibody leads to impaired Salmonella 
killing by neutrophils 288,319. However, to assess neutrophil-selective GM-CSF and IFN-γ 
receptor signalling in context of de novo MHC class II expression in systemic Salmonella 
enterica serovar Typhimurium infection, it would be interesting to generate transgenic 
mouse strains with neutrophil-restricted deficiencies in GM-CSF- and IFN-γ receptors. We 
plan to cross CSF2rbfl mice (provided by Prof. Dr. Burkhard Becher group 320) to the 
Catchup mouse (C57BL/6-Ly6g(tm2621(Cre-tdTomato)Arte), generated by Prof. Dr. 
Matthias Gunzer group 307) with the help of Cre/loxP recombination system and gene 
targeting, which should show target-oriented deletions in neutrophils for GM-CSF receptor. 
Moreover, we want to cross the Ifngr1tm1 mice (provided by Prof. Dr. Daniel Pinschewer) to 
the Catchup mouse to delete target-oriented in neutrophils for IFN-γ receptor. We expect 
that these breedings will lead to mice with normal neutrophil numbers in the periphery, but 
lack in receptors for GM-CSF and IFN-γ respectively 307,320.  
We will regularly perform breeding maintenance (PCR analysis for all mouse strains to confirm 
 
 
126 
the genetic construct C57BL/6-Ly6g(tm2621(Cre-tdTomato)Arte, CSF2rbfl,, Ifngr1tm1) as well as 
target-oriented breeding (PCR analysis for newly constructed mouse strains C57BL/6-
Ly6g(tm2621(Cre-tdTomato)Arte x CSF2rbfl, and Ly6g(tm2621(Cre-tdTomato)Arte x  Ifngr1tm1), 
genotyping and testing for IFN-γ- and GM-CSF receptor expression on neutrophils with Ly6G (or 
tdTomato+ cells or alternative gating approach for neutrophils according to literature 307), Ly6C, 
CD11b for flow cytometry and PCR analysis for Ifngr1 and gsf2rb. Moreover, we will test the 
novel transgenic strains for abnormalities of circulating monocyte and neutrophil numbers. With 
the help of transgenic mouse strains with neutrophil-restricted deficiencies in GM-CSF- and IFN-
γ receptors, we could finally elaborate the role of GM-CSF- and IFN-γ specifically on neutrophils 
in terms of MHC class II induction in vivo.  
 
To understand the classical neutrophil effector functions in APC-like neutrophils in a 
systemic Salmonella infection mouse model 
We would like to test other important neutrophil effector functions such as ROS production 
and pathogen killing in vivo, as previously shown by co-workers 46,288, in the transgenic 
mouse strain with neutrophil-restricted deficiencies in MHC class II in response to systemic 
Salmonella infection. To determine whether APC-like neutrophils in the mouse model show 
impairments in their antimicrobial capacity we will use Salmonella reporter strains 288 which 
allow in situ visualization of the neutrophil/pathogen interaction by immunohistochemistry 
and ex vivo analysis by fluorescence activated cell sorting. To determine whether APC-like 
neutrophils are still able to effectively release ROS in situ and ex vivo, we will use a H2O2 
Salmonella biosensor construct to report ROS exposure in tissue together with neutrophil 
markers CD11b, Ly6G and I-A/I-E. The H2O2 Salmonella biosensor construct pkatGp-gfp 
was previously described 46,288. To determine whether APC-like neutrophils are still able to 
effectively kill Salmonella in vivo and ex vivo, we will use a Salmonella RFP reporter strain 
(Salmonella enterica serovar Typhimurium SL1344 sifBp::mCherry 288) together with 
antibodies against bacterial LPS and antibodies against the neutrophil markers CD11b, 
Ly6G and I-A/I-E to assess whether residing Salmonella within MHC class II+ and MHC 
class II- neutrophils are viable (RFP+LPS+) or dead (RFP-LPS+). 
 
To elaborate the proteome changes of APC-like neutrophils compared to classical 
neutrophils in a systemic Salmonella infection mouse model 
We demonstrated the presence of APC-like neutrophils in vivo in a well-established mouse 
model of systemic salmonellosis 247,248 by using proteome data sets obtained from splenic 
neutrophils of mice infected with Salmonella enterica serovar Typhimurium. However, it 
would be of great interest to identify proteome changes in MHC class II+ and MHC class II- 
neutrophils.  
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We will isolate MHC class II+ and MHC class II- neutrophils from single cell suspensions of 
Salmonella- infected organs by fluorescence activated cell sorting and analyse the organ-
specific neutrophil proteome. 
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8 Conclusion 
Together, these data showed that infectious disease control implies a specialized and 
highly versatile immune system with diverse neutrophil functionality. We showed that 
“simple foot soldier” neutrophils are important for host defense against bacterial and fungal 
pathogens by producing large amounts of ROS. MPO, one of the key enzymes in ROS 
production, has a protective role in the host by scavenging diffusible H2O2 at the 
Salmonella surface and converting it into highly reactive HOCl, which leads to both 
effective pathogen destruction and minimal collateral host tissue damage (Fig. 5).  
 
Neutrophils as “versatile commanders” are unambiguously involved in the pathogenesis of 
sepsis, the dysregulated host response to infection. We could show that under 
inflammatory conditions, the MHC class II enhanceosome is responsible for the 
subsequent MHC class II expression on neutrophils, ultimately leading to T-cell activation. 
Targeting JAK1/2 kinase in neutrophils could be a promising therapeutic approach in 
sepsis. Overall, the immunological function of neutrophils in infectious diseases is highly 
versatile and goes far beyond simple pathogen destruction (Fig. 6).  
Fig. 5: The role of neutrophils as simple foot soldiers of immunity in infectious diseases.  
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Fig. 6: The role of neutrophils as versatile commanders of immunity in infectious diseases.  
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